{"paper_id": "917798a8228960f65244fc232a05e4792cae1ac2", "metadata": {"title": "Journal Pre-proof COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Running Head: COVID-19 and Thrombotic Disease", "authors": [{"first": "Behnood", "middle": [], "last": "Bikdeli", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Mahesh", "middle": ["V"], "last": "Madhavan", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "David", "middle": [], "last": "Jimenez", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Taylor", "middle": [], "last": "Chuich", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Isaac", "middle": [], "last": "Dreyfus", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Elissa", "middle": [], "last": "Driggin", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Caroline", "middle": [], "last": "Der Nigoghossian", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Walter", "middle": [], "last": "Ageno", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Insubria", "location": {"settlement": "Varese", "country": "Italy"}}, "email": ""}, {"first": "Mohammad", "middle": [], "last": "Madjid", "suffix": "", "affiliation": {"laboratory": "", "institution": "The University of Texas Health Science Center at Houston", "location": {"settlement": "Houston", "region": "Texas"}}, "email": ""}, {"first": "Yutao", "middle": [], "last": "Guo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese PLA General Hospital", "location": {"settlement": "Beijing", "country": "China"}}, "email": ""}, {"first": "Liang", "middle": ["V"], "last": "Tang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"settlement": "Wuhan", "country": "China"}}, "email": ""}, {"first": "Yu", "middle": [], "last": "Hu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"settlement": "Wuhan", "country": "China"}}, "email": ""}, {"first": "Jay", "middle": [], "last": "Giri", "suffix": "", "affiliation": {"laboratory": "", "institution": "Hospital of the University of Pennsylvania", "location": {"settlement": "Philadelphia"}}, "email": ""}, {"first": "Mary", "middle": [], "last": "Cushman", "suffix": "", "affiliation": {"laboratory": "", "institution": "The University of Vermont Medical Center", "location": {"settlement": "Burlington", "region": "Vermont"}}, "email": ""}, {"first": "Isabelle", "middle": [], "last": "Qu\u00e9r\u00e9", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Montpellier", "location": {"settlement": "Montpellier CHU, Montpellier", "country": "France"}}, "email": ""}, {"first": "Evangelos", "middle": ["P"], "last": "Dimakakos", "suffix": "", "affiliation": {"laboratory": "", "institution": "Sotiria General Hospital Athens School of Medicine", "location": {"settlement": "Athens", "country": "Greece"}}, "email": ""}, {"first": "C", "middle": ["Michael"], "last": "Gibson", "suffix": "", "affiliation": {"laboratory": "", "institution": "Harvard Medical School", "location": {"settlement": "Boston", "region": "Massachusetts"}}, "email": ""}, {"first": "Giuseppe", "middle": [], "last": "Lippi", "suffix": "", "affiliation": {"laboratory": "Laboratory of Clinical Chemistry and Hematology", "institution": "University Hospital of Verona", "location": {"settlement": "Verona", "country": "Italy"}}, "email": ""}, {"first": "Emmanuel", "middle": ["J"], "last": "Favaloro", "suffix": "", "affiliation": {"laboratory": "Laboratory Haematology", "institution": "Westmead Hospital", "location": {"settlement": "Westmead", "region": "NSW", "country": "Australia"}}, "email": ""}, {"first": "Jawed", "middle": [], "last": "Fareed", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Joseph", "middle": ["A"], "last": "Caprini", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Chicago", "location": {"settlement": "Chicago", "region": "Illinois"}}, "email": ""}, {"first": "Alfonso", "middle": ["J"], "last": "Tafur", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Chicago", "location": {"settlement": "Chicago", "region": "Illinois"}}, "email": ""}, {"first": "John", "middle": ["R"], "last": "Burton", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Dominic", "middle": ["P"], "last": "Francese", "suffix": "", "affiliation": {"laboratory": "", "institution": "Cardiovascular Research Foundation", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Elizabeth", "middle": ["Y"], "last": "Wang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Anna", "middle": [], "last": "Falanga", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Milan Bicocca", "location": {"settlement": "Monza"}}, "email": ""}, {"first": "Claire", "middle": [], "last": "Mclintock", "suffix": "", "affiliation": {"laboratory": "", "institution": "Auckland City Hospital", "location": {"addrLine": "25 St", "settlement": "Auckland", "region": "New Zealand"}}, "email": ""}, {"first": "Beverley", "middle": ["J"], "last": "Hunt", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Alex", "middle": ["C"], "last": "Spyropoulos", "suffix": "", "affiliation": {"laboratory": "The Donald and Barbara Zucker", "institution": "", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Geoffrey", "middle": ["D"], "last": "Barnes", "suffix": "", "affiliation": {}, "email": ""}, {"first": "John", "middle": ["W"], "last": "Eikelboom", "suffix": "", "affiliation": {"laboratory": "", "institution": "McMaster University and Hamilton Health Sciences", "location": {"settlement": "Hamilton", "region": "Ontario", "country": "Canada"}}, "email": ""}, {"first": "Ido", "middle": [], "last": "Weinberg", "suffix": "", "affiliation": {"laboratory": "", "institution": "Massachusetts General Hospital", "location": {"settlement": "Boston", "region": "Massachusetts"}}, "email": ""}, {"first": "Sam", "middle": [], "last": "Schulman", "suffix": "", "affiliation": {"laboratory": "", "institution": "I.M. Sechenov First Moscow State Medical University", "location": {"settlement": "Moscow", "country": "Russia"}}, "email": ""}, {"first": "Marc", "middle": [], "last": "Carrier", "suffix": "", "affiliation": {"laboratory": "", "institution": "The Ottawa Hospital Research Institute", "location": {"settlement": "Ottawa", "region": "Ontario", "country": "Canada"}}, "email": ""}, {"first": "Gregory", "middle": [], "last": "Piazza", "suffix": "", "affiliation": {"laboratory": "", "institution": "Harvard Medical School", "location": {"settlement": "Boston", "region": "Massachusetts"}}, "email": ""}, {"first": "Joshua", "middle": ["A"], "last": "Beckman", "suffix": "", "affiliation": {"laboratory": "", "institution": "Vanderbilt University School of Medicine", "location": {"settlement": "Nashville", "region": "Tennessee"}}, "email": ""}, {"first": "P", "middle": ["Gabriel"], "last": "Steg", "suffix": "", "affiliation": {"laboratory": "FACT (French Alliance for Cardiovascular Trials)", "institution": "H\u00f4pital Bichat", "location": {"postCode": "INSERM U1148", "settlement": "Paris", "country": "France"}}, "email": ""}, {"first": "Gregg", "middle": ["W"], "last": "Stone", "suffix": "", "affiliation": {"laboratory": "", "institution": "Cardiovascular Research Foundation", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Stephan", "middle": [], "last": "Rosenkranz", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Cologne", "location": {"settlement": "Germany"}}, "email": ""}, {"first": "Samuel", "middle": ["Z"], "last": "Goldhaber", "suffix": "", "affiliation": {"laboratory": "", "institution": "Harvard Medical School", "location": {"settlement": "Boston", "region": "Massachusetts"}}, "email": ""}, {"first": "Sahil", "middle": ["A"], "last": "Parikh", "suffix": "", "affiliation": {"laboratory": "", "institution": "Columbia University Irving Medical Center", "location": {"settlement": "New York", "region": "New York"}}, "email": ""}, {"first": "Manuel", "middle": [], "last": "Monreal", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Harlan", "middle": ["M"], "last": "Krumholz", "suffix": "", "affiliation": {"laboratory": "", "institution": "Yale School of Medicine", "location": {"settlement": "New Haven, Connecticut"}}, "email": ""}, {"first": "Stavros", "middle": ["V"], "last": "Konstantinides", "suffix": "", "affiliation": {"laboratory": "", "institution": "Johannes Gutenberg University of Mainz", "location": {"settlement": "Mainz", "country": "Germany"}}, "email": ""}, {"first": "Jeffrey", "middle": ["I"], "last": "Weitz", "suffix": "", "affiliation": {"laboratory": "", "institution": "McMaster University", "location": {"settlement": "Hamilton", "region": "Ontario", "country": "Canada"}}, "email": ""}, {"first": "Gregory", "middle": ["Y H"], "last": "Lip", "suffix": "", "affiliation": {"laboratory": "Liverpool Centre for Cardiovascular Science", "institution": "University of Liverpool and Liverpool Heart & Chest Hospital", "location": {"settlement": "Liverpool", "country": "United Kingdom"}}, "email": ""}, {"first": "Bikdeli", "middle": ["B"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Madhavan", "middle": [], "last": "Mv", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jimenez", "middle": ["D"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Nigoghossian", "middle": [], "last": "Cd", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ageno", "middle": ["W"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Madjid", "middle": ["M"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Guo", "middle": ["Y"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tang", "middle": [], "last": "Lv", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Hu", "middle": ["Y"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Giri", "middle": ["J"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Cushman", "middle": ["M"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Gibson", "middle": [], "last": "Cm", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Lippi", "middle": ["G"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Favaloro", "middle": [], "last": "Ej", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Fareed", "middle": ["J"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Caprini", "middle": [], "last": "Ja", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tafur", "middle": [], "last": "Aj", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Burton", "middle": [], "last": "Jr", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Francese", "middle": [], "last": "Dp", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wang", "middle": [], "last": "Ey", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Falanga", "middle": ["A"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Mclintock", "middle": ["C"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Hunt", "middle": [], "last": "Bj", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Spyropoulos", "middle": [], "last": "Ac", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Barnes", "middle": [], "last": "Gd", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Eikelboom", "middle": [], "last": "Jw", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Weinberg", "middle": ["I"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Schulman", "middle": ["S"], "last": "Carrier", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Piazza", "middle": ["G"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Beckman", "middle": [], "last": "Ja", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Steg", "middle": [], "last": "Pg", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Parikh", "middle": [], "last": "Sz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Monreal", "middle": ["M"], "last": "Sa", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Krumholz", "middle": [], "last": "Hm", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Konstantinides", "middle": [], "last": "Sv", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Weitz", "middle": [], "last": "Ji", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), now deemed a pandemic by the World Health Organization (1) (2) (3) . COVID-19 has a number of important cardiovascular implications (4) (5) (6) . Patients with prior cardiovascular disease are at higher risk for adverse events from COVID- 19 . Individuals without a history of cardiovascular disease are at risk for incident cardiovascular complications (5) .", "cite_spans": [{"start": 192, "end": 195, "text": "(1)", "ref_id": "BIBREF0"}, {"start": 196, "end": 199, "text": "(2)", "ref_id": null}, {"start": 200, "end": 203, "text": "(3)", "ref_id": "BIBREF3"}, {"start": 269, "end": 272, "text": "(4)", "ref_id": "BIBREF4"}, {"start": 273, "end": 276, "text": "(5)", "ref_id": "BIBREF5"}, {"start": 277, "end": 280, "text": "(6)", "ref_id": "BIBREF6"}, {"start": 376, "end": 378, "text": "19", "ref_id": "BIBREF19"}, {"start": 491, "end": 494, "text": "(5)", "ref_id": "BIBREF5"}], "ref_spans": [], "section": "Introduction"}, {"text": "There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease (hereafter collectively referred to as thrombotic disease for brevity). First, the direct effects of COVID-19 or the indirect effects of infection, such as through severe illness and hypoxia, may predispose patients to thrombotic events. Preliminary reports suggest that hemostatic abnormalities, including disseminated intravascular coagulation (DIC), occur in patients affected by COVID-19 (7, 8) . Additionally, the severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks (Table   1 ) (9, 10) . Second, investigational therapies for treating COVID-19 may have adverse drug-drug interactions with antiplatelet agents and anticoagulants. Third, the pandemic, because of resource allocations or social distancing recommendations, may adversely affect the care of patients without COVID-19 but who present with thrombotic events. For example, (mis)perception that antithrombotic agents confer increased risk for contracting COVID-19, may lead to untoward interruption of anticoagulation by some patients.", "cite_spans": [{"start": 528, "end": 531, "text": "(7,", "ref_id": "BIBREF7"}, {"start": 532, "end": 534, "text": "8)", "ref_id": "BIBREF8"}, {"start": 754, "end": 757, "text": "(9,", "ref_id": "BIBREF9"}, {"start": 758, "end": 761, "text": "10)", "ref_id": "BIBREF10"}], "ref_spans": [{"start": 741, "end": 751, "text": "(Table   1", "ref_id": "TABREF3"}], "section": "Introduction"}, {"text": "The current manuscript, authored by an international collaborative of clinicians and investigators, summarizes the pathogenesis, epidemiology, treatment, and available outcome data related to thrombotic disease in patients with COVID-19, as well as management of thrombotic events in patients without COVID-19 during this pandemic. Although the focus is on the prevention and management of venous thromboembolism (VTE) and antithrombotic therapy for acute coronary syndromes (ACS), many of the recommendations are relevant to other conditions requiring antithrombotic therapy. We provide clinical guidance, when feasible, and also identify areas that require urgent attention for future research.", "cite_spans": [], "ref_spans": [], "section": "Introduction"}, {"text": "Every effort was made to provide a comprehensive assessment of the published evidence (MEDLINE with PubMed interface, date of last search: April 12, 2020) . To accommodate the rapidly-evolving nature of information and concern for the delay between completion of studies and their publication, we also reviewed manuscripts on two pre-print servers (https://www.medrxiv.org/ and https://www.ssrn.com/index.cfm/en/coronavirus/, date of last search April 12, 2020) . We acknowledge that the manuscripts from the latter two sources are not peer-reviewed.", "cite_spans": [{"start": 139, "end": 154, "text": "April 12, 2020)", "ref_id": null}, {"start": 446, "end": 461, "text": "April 12, 2020)", "ref_id": null}], "ref_spans": [], "section": "Methodological Considerations"}, {"text": "There is international variability in preventive measures and testing strategies by local authorities, diagnostic tests availability, access to care and treatment strategies, as well as variability in outcome reporting for COVID-19. These issues influence the reported diagnosed cases, casualties, and in turn case-fatality rates. Moreover, to date, we lack large prospective cohorts. The existing evidence, including data on thrombotic complications, is derived primarily from small and retrospective analyses (Figure 1 ).", "cite_spans": [], "ref_spans": [{"start": 511, "end": 520, "text": "(Figure 1", "ref_id": null}], "section": "Methodological Considerations"}, {"text": "The current document represents an effort to provide general guidance for patient-care related to thrombosis and antithrombotic therapy. Given the limitations of the evidence base, the steering committee (BB, MVM, JIW, SK, SZG, AT, MM, HMK, GYHL) chose several questions that seemed more challenging but relevant to patient care (11) . These questions were sent to the entire group of authors twice. The Delphi method was implemented to provide consensus-based guidance. The questions included considerations for prophylactic or therapeutic anticoagulant regimens among various subgroups of patients with COVID-19, and antithrombotic therapy in the setting of suspected or confirmed DIC.", "cite_spans": [{"start": 329, "end": 333, "text": "(11)", "ref_id": "BIBREF11"}], "ref_spans": [], "section": "Methodological Considerations"}, {"text": "SARS-CoV2 is a single-strand RNA coronavirus, which enters human cells mainly by binding the angiotensin converting enzyme 2 (ACE2) (12) , which is highly expressed in lung alveolar cells, cardiac myocytes, the vascular endothelium, and other cells (1, 13) . SARS-CoV2 is transmitted primarily after viral particles are inhaled and enter the respiratory tract (1) . In addition, the virus can survive for 24-72 hours on surfaces, depending on the type of surface, which enables fomite transmission (14) .", "cite_spans": [{"start": 132, "end": 136, "text": "(12)", "ref_id": "BIBREF12"}, {"start": 249, "end": 252, "text": "(1,", "ref_id": "BIBREF0"}, {"start": 253, "end": 256, "text": "13)", "ref_id": "BIBREF13"}, {"start": 360, "end": 363, "text": "(1)", "ref_id": "BIBREF0"}, {"start": 498, "end": 502, "text": "(14)", "ref_id": "BIBREF14"}], "ref_spans": [], "section": "Pathogenesis and Transmission"}, {"text": "Initial symptoms of COVID-19 overlap with other viral syndromes, and include fever, fatigue, headache, cough, shortness of breath, diarrhea, headaches, and myalgias (15) (16) (17) . As with other virulent zoonotic coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has the potential to result in severe illness including systemic inflammatory response syndrome, acute respiratory disease syndrome (ARDS), multi-organ involvement, and shock (18) . Although older age and comorbidities such as cardiovascular disease confer a higher risk for severe disease, young and otherwise healthy patients are also at risk for complications (19) .", "cite_spans": [{"start": 165, "end": 169, "text": "(15)", "ref_id": "BIBREF15"}, {"start": 170, "end": 174, "text": "(16)", "ref_id": "BIBREF16"}, {"start": 175, "end": 179, "text": "(17)", "ref_id": "BIBREF17"}, {"start": 522, "end": 526, "text": "(18)", "ref_id": "BIBREF18"}, {"start": 710, "end": 714, "text": "(19)", "ref_id": "BIBREF19"}], "ref_spans": [], "section": "Pathogenesis and Transmission"}, {"text": "Common laboratory abnormalities found in patients with COVID-19 include lymphopenia (15) and elevation in lactate dehydrogenase and inflammatory markers such as, C-reactive protein, D-dimer, ferritin and interleukin-6 (IL-6) (20) . IL-6 levels may correlate with disease severity, and a procoagulant profile (21) .", "cite_spans": [{"start": 84, "end": 88, "text": "(15)", "ref_id": "BIBREF15"}, {"start": 225, "end": 229, "text": "(20)", "ref_id": "BIBREF20"}, {"start": 308, "end": 312, "text": "(21)", "ref_id": "BIBREF21"}], "ref_spans": [], "section": "Pathogenesis and Transmission"}, {"text": "The most consistent hemostatic abnormalities with COVID-19 include mild thrombocytopenia (22) and increased D-dimer levels (23) , which are associated with a higher risk of requiring mechanical ventilation, intensive care unit [ICU] admission, or death. Data related to other tests are less certain and often contradictory (24, 25) . Disease severity is variably associated with prolongation of the prothrombin time (PT) and international normalized ratio (INR) (1, 20, 26) , and thrombin time (TT) (27) , and variably by a trend toward shortened activated partial thromboplastin time (aPTT) (1, 16, 19, 28) . Recently, Tang et al. (7) assessed 183 patients with COVID-19, 21 of whom (11.5%) died. Among the notable differences between patients who died and those who survived were increased levels of D-dimer and fibrin degradation products ([FDPs], ~3.5-and ~1.9-fold increase, respectively) and PT prolongation (by 14%, P<0.001). Further, 71% of COVID-19 patients who died fulfilled the International Society on Thrombosis and Haemostasis (ISTH) criteria (29) for DIC, compared with only 0.6% among survivors. Collectively, these hemostatic changes indicate some forms of coagulopathy that may predispose to thrombotic events (Central Illustration), although the cause is uncertain.", "cite_spans": [{"start": 89, "end": 93, "text": "(22)", "ref_id": "BIBREF22"}, {"start": 123, "end": 127, "text": "(23)", "ref_id": "BIBREF23"}, {"start": 323, "end": 327, "text": "(24,", "ref_id": "BIBREF24"}, {"start": 328, "end": 331, "text": "25)", "ref_id": "BIBREF25"}, {"start": 462, "end": 465, "text": "(1,", "ref_id": "BIBREF0"}, {"start": 466, "end": 469, "text": "20,", "ref_id": "BIBREF20"}, {"start": 470, "end": 473, "text": "26)", "ref_id": "BIBREF27"}, {"start": 499, "end": 503, "text": "(27)", "ref_id": "BIBREF28"}, {"start": 592, "end": 595, "text": "(1,", "ref_id": "BIBREF0"}, {"start": 596, "end": 599, "text": "16,", "ref_id": "BIBREF16"}, {"start": 600, "end": 603, "text": "19,", "ref_id": "BIBREF19"}, {"start": 604, "end": 607, "text": "28)", "ref_id": "BIBREF29"}, {"start": 632, "end": 635, "text": "(7)", "ref_id": "BIBREF7"}, {"start": 1058, "end": 1062, "text": "(29)", "ref_id": "BIBREF30"}], "ref_spans": [], "section": "COVID-19 and Hemostasis Parameters"}, {"text": "Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic inflammatory response syndrome (SIRS), as observed in other viral disease (30-33). Another consideration which has not yet been investigated is that the hemostatic changes seen with COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the setting of elevated antiphospholipid antibodies. Whether antiphospholipid antibodies play a major role in pathophysiology of thrombosis associated with COVID-19 requires further investigation (35).", "cite_spans": [], "ref_spans": [], "section": "COVID-19 and Hemostasis Parameters"}, {"text": "Elevated troponin levels are associated with poor outcomes in several studies of COVID-19 (36). However, the differential diagnosis for elevated troponin in COVID-19 is broad (37) and includes non-specific myocardial injury, impaired renal function (leading to troponin accumulation), myocarditis, pulmonary embolism (PE), and Type I and II myocardial infarction (MI) (38,39). Similarly, elevation of natriuretic peptides is non-specific (38), and consideration for thrombotic events (e.g., PE) should only be raised in the appropriate clinical context.", "cite_spans": [], "ref_spans": [], "section": "COVID-19, markers of myocardial injury, and thrombotic disease."}, {"text": "Several investigational agents are being tested in the management of COVID-19, especially for patients who develop severe disease. Some of these drugs have clinically important interactions with antiplatelet or anticoagulant agents (Tables 4 and 5) .", "cite_spans": [], "ref_spans": [{"start": 232, "end": 248, "text": "(Tables 4 and 5)", "ref_id": "TABREF0"}], "section": "COVID-19 Investigational Therapies and Considerations for Thrombotic Disease"}, {"text": "Further, a few of these investigational agents have been associated with excess risk (or, in other cases, reduced risk) for thrombotic events, or for thrombocytopenia in prior studies of non-COVID-19 populations. For example, bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), and is under investigational use for COVID-19, is associated with increased risk for adverse cardiovascular events, including MI, cerebrovascular accidents, and VTE (40,41). Alternatively, fingolimod, an immunomodulating agent being tried for COVID-19, may reduce reperfusion injury and improve outcomes in patients suffering from acute ischemic stroke (42). Hydroxychorloquine, recently receiving Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of COVID-19, may potentially exert antithrombotic properties, especially against anti-phospholipid antibodies (43).", "cite_spans": [], "ref_spans": [], "section": "COVID-19 Investigational Therapies and Considerations for Thrombotic Disease"}, {"text": "Scientists are studying a number of agents for COVID-19 treatment that may have interactions with oral antiplatelet agents. Table 3 presents potential drug interactions between investigational drugs for COVID-19 and commonly administered oral antiplatelet agents.", "cite_spans": [], "ref_spans": [{"start": 124, "end": 131, "text": "Table 3", "ref_id": null}], "section": "COVID-19 investigational therapies and antiplatelet agents."}, {"text": "Lopinavir/ritonavir is a protease inhibitor and inhibits CYP3A4 metabolism. Although the active metabolite for clopidogrel is mostly formed by CYP2C19, inhibition of CYP3A4 may also lead to reduction in effective dosage of clopidogrel. In contrast, inhibition of CYP3A4 may increase effects of ticagrelor. Therefore, the concomitant use of these agents along with lopinavir/ritonavir should be cautioned. Although limited clinical data exist, use of P2Y 12 platelet function testing to guide the use of clopidogrel or ticagrelor in this setting might be considered.", "cite_spans": [], "ref_spans": [], "section": "COVID-19 investigational therapies and antiplatelet agents."}, {"text": "An alternative, in the absence of contraindications, is to use prasugrel, which is not prone to these interactions (44-47). Remdesivir, a nucleotide-analog inhibitor of RNA-dependent RNA polymerase, reportedly an inducer of CYP3A4; however, dose adjustments for oral antiplatelet agents are currently not recommended. Of note, there are no major drug-drug interactions between investigational COVID-19 therapies and parenteral antiplatelet agents such as cangrelor and glycoprotein IIb/IIIa inhibitors. ", "cite_spans": [], "ref_spans": [], "section": "COVID-19 investigational therapies and antiplatelet agents."}, {"text": "Hospitalized patients with acute medical illness, including infections such as pneumonia, are at increased risk of VTE (48,49). Prophylactic anticoagulation reduces the risk of VTE in acutely ill hospitalized medical patients (50) (51) (52) , and appropriate use of VTE prophylaxis is covered in clinical practice guidelines (49, 53, 54) . Multiple risk stratification tools are available for VTE risk assessment in this setting (e.g. the Caprini, IMPROVE, and Padua models) (55-60).", "cite_spans": [{"start": 226, "end": 230, "text": "(50)", "ref_id": "BIBREF32"}, {"start": 231, "end": 235, "text": "(51)", "ref_id": null}, {"start": 236, "end": 240, "text": "(52)", "ref_id": "BIBREF35"}, {"start": 325, "end": 329, "text": "(49,", "ref_id": "BIBREF31"}, {"start": 330, "end": 333, "text": "53,", "ref_id": "BIBREF36"}, {"start": 334, "end": 337, "text": "54)", "ref_id": "BIBREF37"}], "ref_spans": [], "section": "Risk stratification and in-hospital prophylaxis."}, {"text": "The choice of specific risk assessment model may vary across health system. However, similar to other acutely ill medical patients, VTE risk stratification for hospitalized patients with COVID-19 should be undertaken. A recent study from China, using the Padua model, reported that 40% of hospitalized patients with COVID-19 were at high risk of VTE. The study did not provide data about the use of VTE prophylaxis, or the incident VTE events (61). Hospitalized patients with COVID-19 who have respiratory failure or co-morbidities (e.g., active cancer, or heart failure) (62), patients who are bedridden, and those requiring intensive care should receive pharmacological VTE prophylaxis, unless there are contraindications. The choice of agents and dosing should be based on available guideline recommendations (53, 54, 63) . The World Health Organization interim guidance statement recommends prophylactic daily low-molecular weight heparins (LMWHs), or twice daily subcutaneous unfractionated heparin (UFH) (64) . If pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent pneumatic compression) should be considered in immobilized patients (64, 65) . Missed doses of pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes (66) . Therefore, every effort should be made to ensure that patients receive all scheduled doses of pharmacologic VTE prophylaxis. In this regard, once daily dosing regimen of LMWHs may be advantageous over UFH to reduce personal protective equipment (PPE) use and exposure of healthcare workers.", "cite_spans": [{"start": 812, "end": 816, "text": "(53,", "ref_id": "BIBREF36"}, {"start": 817, "end": 820, "text": "54,", "ref_id": "BIBREF37"}, {"start": 821, "end": 824, "text": "63)", "ref_id": null}, {"start": 1010, "end": 1014, "text": "(64)", "ref_id": "BIBREF40"}, {"start": 1177, "end": 1181, "text": "(64,", "ref_id": "BIBREF40"}, {"start": 1182, "end": 1185, "text": "65)", "ref_id": "BIBREF41"}, {"start": 1291, "end": 1295, "text": "(66)", "ref_id": "BIBREF42"}], "ref_spans": [], "section": "Risk stratification and in-hospital prophylaxis."}, {"text": "Consideration for risk of VTE in pregnant patients with COVID-19 deserves further attention. The risk of VTE is increased during pregnancy and the postpartum period (67, 68) .", "cite_spans": [{"start": 165, "end": 169, "text": "(67,", "ref_id": "BIBREF43"}, {"start": 170, "end": 173, "text": "68)", "ref_id": "BIBREF44"}], "ref_spans": [], "section": "Risk stratification and in-hospital prophylaxis."}, {"text": "Although limited data are available, pregnant women admitted to hospital with COVID-19", "cite_spans": [], "ref_spans": [], "section": "Risk stratification and in-hospital prophylaxis."}, {"text": "infection are likely to be at an increased risk of VTE. It is reasonable to assess the risk of VTE and to consider pharmacological thromboprophylaxis, especially if they have other VTE risk factors. Weight-adjusted prophylactic dosing of anticoagulation is an interesting topic that requires additional investigation (69) .", "cite_spans": [{"start": 317, "end": 321, "text": "(69)", "ref_id": "BIBREF45"}], "ref_spans": [], "section": "Risk stratification and in-hospital prophylaxis."}, {"text": "After hospital discharge from acute medical illness, extended prophylaxis with LMWH (70) or direct oral anticoagulants (DOACs) (71) (72) (73) (74) can reduce the risk of VTE, at the cost of increase in bleeding events, including major bleeding (75, 76) . While no data specific to COVID-19 exist, it is reasonable to employ individualized risk stratification for thrombotic and hemorrhagic risk, followed by consideration of extended prophylaxis (for up to 45 days) for patients with elevated risk of VTE (e.g., reduced mobility, co-morbidities such as active cancer, and [according to some authors in the writing group], elevated D-dimer >2 times the upper normal limit) who have low risk of bleeding (74, 77, 78) .", "cite_spans": [{"start": 84, "end": 88, "text": "(70)", "ref_id": "BIBREF46"}, {"start": 127, "end": 131, "text": "(71)", "ref_id": "BIBREF47"}, {"start": 132, "end": 136, "text": "(72)", "ref_id": "BIBREF48"}, {"start": 137, "end": 141, "text": "(73)", "ref_id": "BIBREF49"}, {"start": 142, "end": 146, "text": "(74)", "ref_id": "BIBREF50"}, {"start": 244, "end": 248, "text": "(75,", "ref_id": "BIBREF51"}, {"start": 249, "end": 252, "text": "76)", "ref_id": "BIBREF52"}, {"start": 702, "end": 706, "text": "(74,", "ref_id": "BIBREF50"}, {"start": 707, "end": 710, "text": "77,", "ref_id": "BIBREF53"}, {"start": 711, "end": 714, "text": "78)", "ref_id": "BIBREF54"}], "ref_spans": [], "section": "Extended (post-discharge) VTE prophylaxis."}, {"text": "The role of thromboprophylaxis for quarantined patients with mild COVID-19 but significant co-morbidities, or for patients without COVID-19 who are less active because of quarantine is uncertain. These patients should be advised to stay active at home. In the absence of high-quality data, pharmacological prophylaxis should be reserved for those at highest risk patients, including those with limited mobility and history of prior VTE or active malignancy.", "cite_spans": [], "ref_spans": [], "section": "Extended (post-discharge) VTE prophylaxis."}, {"text": "As described above, elevated D-dimer levels, is a common finding in patients with COVID-19 (23), and does not currently warrant routine investigation for acute VTE in absence of clinical manifestations or other supporting information. However, the index of suspicion for VTE should be high in the case typical DVT symptoms, hypoxemia disproportionate to known respiratory pathologies, or acute unexplained right ventricular dysfunction.", "cite_spans": [], "ref_spans": [], "section": "Diagnosis of VTE in patients with COVID-19."}, {"text": "A diagnostic challenge arises among patients with COVID-19, as imaging studies used to diagnose DVT or PE may not be pursued given risk of transmitting infection to other patients or healthcare workers and potentially due to patient instability. Moreover, imaging studies may be challenging in the setting of patients with severe ARDS who require prone positioning.", "cite_spans": [], "ref_spans": [], "section": "Diagnosis of VTE in patients with COVID-19."}, {"text": "Investigation for PE is not feasible due to critical illness and prone position. Lower extremity ultrasound is also limited due to patient positioning. Deterioration of right ventricular function in this setting may be a critical finding, justifying the need for ways to diagnose and treat PE.", "cite_spans": [], "ref_spans": [], "section": "Diagnosis of VTE in patients with COVID-19."}, {"text": "However, it may be argued that the prognosis of patients with ARDS requiring prone position is so grave that investigation for underlying VTE may not alter the course. A potential option may be to consider echocardiography to assess for signs of potentially worsening right ventricular dysfunction and in rare circumstances, clot in transit (79).", "cite_spans": [], "ref_spans": [], "section": "Diagnosis of VTE in patients with COVID-19."}, {"text": "In view of the hemostatic derangements discussed above and observations from prior viral illnesses (80), some clinicians use intermediate-dose or full dose (therapeutic) parenteral anticoagulation (rather than prophylactic dosing) for routine care of patients with COVID-19", "cite_spans": [], "ref_spans": [], "section": "Role for empiric therapeutic anticoagulation without a diagnosis of VTE."}, {"text": "(81), hypothesizing that it may confer benefit to prevent microvascular thrombosis. However, the existing data are very limited, primarily based on a subgroup analysis (N=97) from a single retrospective study with limited control for potential confounders (82). A single center study from China suggested that D-dimer levels >1,500ng/mL has a sensitivity of 85.0% and specificity of 88.5% for detecting VTE events. However, the study was limited by small sample ", "cite_spans": [], "ref_spans": [], "section": "Role for empiric therapeutic anticoagulation without a diagnosis of VTE."}, {"text": "Few published studies have commented on incident VTE in patients with COVID-19. In a retrospective study from China, among 81 patients with severe COVID-19 admitted to ICU, 20 (25%) developed incident VTE. Of note, none of the patients had received VTE prophylaxis (85). In an preprint study of 25 patients with COVID-19 from Wuhan, who were suspected of having PE and underwent computed tomography angiography (CTA), 10 (40%) had evidence of acute PE on imaging (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771); however, the study did not provide information related to use of VTE prophylaxis or the reason for performing CTA. In a study of 184 patients with severe COVID-19 from 3 academic medical centers in the Netherlands, the authors reported that 31% (95%CI 20-41) of patients developed incident VTE. All patients received pharmacological prophylaxis, although under-dosing was observed in 2 of the 3 participating centers (81). These findings require validation in additional studies.", "cite_spans": [], "ref_spans": [], "section": "Incident venous thromboembolism."}, {"text": "It is possible but unknown that VTE remains underdiagnosed in patients with severe COVID-19. This is important, as ARDS in patients with COVID-19 is, itself, a potential etiology for hypoxic pulmonary vasoconstriction, pulmonary hypertension and right ventricular failure.", "cite_spans": [], "ref_spans": [], "section": "Incident venous thromboembolism."}, {"text": "Further insult from PE may be unrecoverable.", "cite_spans": [], "ref_spans": [], "section": "Incident venous thromboembolism."}, {"text": "Therapeutic anticoagulation is the mainstay of VTE treatment (49, 86, 87) . Selection of an agent requires consideration of comorbidities such as renal or hepatic dysfunction, thrombocytopenia and gastrointestinal tract function, and the agent will likely change across the hospital course to the time of discharge. In many ill inpatients with VTE, parenteral anticoagulation (e.g. UFH) is preferred as it may be temporarily withheld and has no known drug-drug interactions with investigational COVID-19 therapies. Concerns with UFH, however, include the time to achieve therapeutic aPTT, and increased healthcare worker exposure for frequent blood draws. Therefore, LMWHs may be preferred in patients unlikely to need procedures. The benefit of oral anticoagulation with DOACs include the lack of need for monitoring, facilitation of discharge planning, and outpatient management. The potential risk (especially in the setting or organ dysfunction) may include clinical deterioration and lack of timely availability of effective reversal agents at some centers. For patients who are ready for discharge, DOACs or LMWH would be preferred to limit contact of patients with healthcare services required for INR monitoring for VKAs.", "cite_spans": [{"start": 61, "end": 65, "text": "(49,", "ref_id": "BIBREF31"}, {"start": 66, "end": 69, "text": "86,", "ref_id": null}, {"start": 70, "end": 73, "text": "87)", "ref_id": null}], "ref_spans": [], "section": "Medical therapy for VTE."}, {"text": "Pulmonary embolism response teams (PERTs) allow for multidisciplinary care for patients intermediate and high-risk with VTE (49, (88) (89) (90) . During the COVID-19 pandemic, similar to other consultative services, PERTs should transition from in-person inpatient evaluation to e-consults using phone calls or telemedicine systems whenever feasible. It is important to note that, there are minimal available data demonstrating lower mortality from routine use of advanced VTE therapies (91, 92) . Therefore, the use of catheter-directed therapies during the current outbreak should be limited to the most critical situations. Indiscriminate use of inferior vena cava filters should be avoided (93) . Recurrent PE despite optimal anticoagulation, or clinically-significant VTE in the setting of absolute contraindications to anticoagulation would be among the few scenarios in which placement of an inferior vena cava filter may be considered (11) . Even after IVC filter placement, anticoagulation should be resumed as soon as feasible, and this is often done with gradually increasing doses and close observation for bleeding. With regard to reperfusion strategies for acute PE, current guideline recommendations should be followed. ", "cite_spans": [{"start": 124, "end": 128, "text": "(49,", "ref_id": "BIBREF31"}, {"start": 129, "end": 133, "text": "(88)", "ref_id": "BIBREF55"}, {"start": 134, "end": 138, "text": "(89)", "ref_id": "BIBREF56"}, {"start": 139, "end": 143, "text": "(90)", "ref_id": "BIBREF57"}, {"start": 487, "end": 491, "text": "(91,", "ref_id": "BIBREF58"}, {"start": 492, "end": 495, "text": "92)", "ref_id": "BIBREF59"}, {"start": 694, "end": 698, "text": "(93)", "ref_id": "BIBREF60"}, {"start": 943, "end": 947, "text": "(11)", "ref_id": "BIBREF11"}], "ref_spans": [], "section": "COVID-19 and interventional therapies for VTE."}, {"text": "known COVID-19 positivity or uncertain status, rather than support strategies requiring the use of a catheterization laboratory or an operating room (95) . Figure 2 presents a potential algorithm for treatments based on risk due to VTE and COVID-19 severity.", "cite_spans": [{"start": 149, "end": 153, "text": "(95)", "ref_id": "BIBREF62"}], "ref_spans": [{"start": 156, "end": 164, "text": "Figure 2", "ref_id": "FIGREF5"}], "section": "initiation of extracorporeal membrane oxygenation (ECMO) is preferred in cases with"}, {"text": "The vast majority of patients with symptomatic acute deep venous thrombosis (DVT), should be managed with anticoagulation, with home treatment whenever possible. The few that may require acute endovascular techniques (either local fibrinolysis or embolectomy) include those with phlegmasia, or truly refractory symptoms (96) .", "cite_spans": [{"start": 320, "end": 324, "text": "(96)", "ref_id": "BIBREF64"}], "ref_spans": [], "section": "initiation of extracorporeal membrane oxygenation (ECMO) is preferred in cases with"}, {"text": "Myocardial injury in COVID-19, as evidenced by elevated cardiac troponin levels or electrocardiographic and echocardiographic abnormalities, is associated with severe disease. 7 Furthermore, higher troponin levels are associated with severe COVID-19 (5, 97) . However, not all such events are due to thrombotic ACS. While anecdotal cases of patients with COVID-19 presenting with ACS due to plaque-rupture have been described (type I MI), currently no such cases have been published. Such cases have been also previously described with influenza or other viral illnesses, and have been attributed to a combination of SIRS as well as localized vascular/plaque inflammation (10, 98, 99) .", "cite_spans": [{"start": 176, "end": 177, "text": "7", "ref_id": "BIBREF7"}, {"start": 250, "end": 253, "text": "(5,", "ref_id": "BIBREF5"}, {"start": 254, "end": 257, "text": "97)", "ref_id": "BIBREF65"}, {"start": 672, "end": 676, "text": "(10,", "ref_id": "BIBREF10"}, {"start": 677, "end": 680, "text": "98,", "ref_id": "BIBREF66"}, {"start": 681, "end": 684, "text": "99)", "ref_id": "BIBREF67"}], "ref_spans": [], "section": "COVID-19 and incident ACS."}, {"text": "In presentations consistent with ACS due to plaque rupture (i.e. Type I MI) (39), dual antiplatelet therapy (DAPT) and full dose anticoagulation per American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC) guidelines should be administered unless there are contraindications (100) (101) (102) (103) . In patients with perceived elevated bleeding risk, regimens with less potent antiplatelet agents, such as with clopidogrel, should be considered given that hemorrhagic complications are not uncommon.", "cite_spans": [{"start": 333, "end": 338, "text": "(100)", "ref_id": "BIBREF68"}, {"start": 339, "end": 344, "text": "(101)", "ref_id": "BIBREF69"}, {"start": 345, "end": 350, "text": "(102)", "ref_id": "BIBREF70"}, {"start": 351, "end": 356, "text": "(103)", "ref_id": "BIBREF71"}], "ref_spans": [], "section": "COVID-19 and antithrombotic therapy for ACS."}, {"text": "Special attention should be also given to drug-drug interactions between antiplatelet agents or anticoagulants and COVID-19 investigational therapies. Parenteral antithrombotic agents, in general, do not have known major interactions with the COVID-19 investigational therapies (Tables 4, 5) .", "cite_spans": [], "ref_spans": [{"start": 278, "end": 291, "text": "(Tables 4, 5)", "ref_id": "TABREF0"}], "section": "COVID-19 and antithrombotic therapy for ACS."}, {"text": "Angiography and Interventions (SCAI) recently provided guidance regarding catheterization laboratory procedures in the current climate (84,104). The recommendations note that it is reasonable to continue optimal medical therapy and defer non-urgent cardiac procedures, in order to preserve PPE, hospital resources including inpatient and ICU beds, and minimize exposure for patients and healthcare workers, alike.", "cite_spans": [], "ref_spans": [], "section": "The American College of Cardiology (ACC) and Society for Cardiovascular"}, {"text": "Prior to intervention, efforts should be made to distinguish non-specific myocardial injury, myocarditis, and true plaque rupture presentations (104) . A low threshold to use transthoracic echocardiography to identify wall motion abnormalities should be considered prior to catheterization laboratory activation. Even in case of STEMI, in which primary percutaneous coronary intervention (PCI) reduces mortality and reinfarction, risk of COVID-19 transmission from patients to healthcare workers, or vice versa (asymptomatic vectors) must be considered. In light of this, individual centers in China and elsewhere have developed adjusted ACS protocols, which call for consideration of fibrinolytic therapy in selected patients with STEMI (105) .", "cite_spans": [{"start": 144, "end": 149, "text": "(104)", "ref_id": "BIBREF72"}, {"start": 738, "end": 743, "text": "(105)", "ref_id": "BIBREF73"}], "ref_spans": [], "section": "The American College of Cardiology (ACC) and Society for Cardiovascular"}, {"text": "Centers in which timely percutaneous coronary intervention is less feasible may be more likely to adopt such a strategy. However, given that presentations of COVID-19 can mimic ACS (e.g.", "cite_spans": [], "ref_spans": [], "section": "The American College of Cardiology (ACC) and Society for Cardiovascular"}, {"text": "in the setting of myocarditis), fibrinolytic therapy must be used with caution.", "cite_spans": [], "ref_spans": [], "section": "The American College of Cardiology (ACC) and Society for Cardiovascular"}, {"text": "The risk of VTE, which is increased in critically ill patients, is likely even higher in those with SARS-CoV-2 and critical illness. Aside from hemostatic derangements, immobility, an systemic inflammatory state, mechanical ventilation and central venous catheters contribute to VTE risk within the ICU (106-108), Nutritional deficiencies and liver dysfunction may also interfere with the production of coagulation factors (109) . Alterations in pharmacokinetics in critically ill patients may necessitate anticoagulation dose adjustment (110) , due to factors relating to absorption, metabolism, and renal (or hepatic) elimination of these drugs in the setting of potential organ dysfunction.", "cite_spans": [{"start": 423, "end": 428, "text": "(109)", "ref_id": "BIBREF77"}, {"start": 538, "end": 543, "text": "(110)", "ref_id": "BIBREF78"}], "ref_spans": [], "section": "Critical Illness with SARS-CoV-2 and Management of Antithrombotic Agents"}, {"text": "Parenteral anticoagulation is recommended in most cases in which anticoagulant therapy is needed for known thrombotic disease. UFH can be used in the setting of anticipated procedures, or in patients with deteriorating renal function. If no urgent procedures are anticipated, LMWHs are a reasonable alternative (111) . In patients requiring ECMO, anticoagulation is frequently required to maintain circuit patency, especially at lower flow settings. Rates of complications are unknown in patients with SARS-CoV-2, but rates of thrombosis and hemorrhage may be as high as 53% and 16%, respectively, in other populations with respiratory failure (112) . The limited outcome data that are available for ECMO in patients with SARS-CoV-2 suggest poor outcomes, with 5 of 6 patients dying in one series and 3 out of 3 in another (113, 114) . There are currently insufficient data to recommend anticoagulation targets for COVID-19 patients requiring ECMO (115) .", "cite_spans": [{"start": 311, "end": 316, "text": "(111)", "ref_id": "BIBREF79"}, {"start": 644, "end": 649, "text": "(112)", "ref_id": "BIBREF80"}, {"start": 823, "end": 828, "text": "(113,", "ref_id": "BIBREF81"}, {"start": 829, "end": 833, "text": "114)", "ref_id": "BIBREF82"}, {"start": 948, "end": 953, "text": "(115)", "ref_id": "BIBREF83"}], "ref_spans": [], "section": "Critical Illness with SARS-CoV-2 and Management of Antithrombotic Agents"}, {"text": "As previously mentioned, severe COVID-19 may predispose to DIC with such patients experiencing particularly poor outcomes (7) . Supportive care and addressing the underlying hypoxia or co-infection are appropriate (29) . There are insufficient data to recommend transfusion thresholds that differ from those recommended for other critically ill patients. If invasive procedures are planned, prophylactic transfusion of platelets, fresh frozen plasma, fibrinogen, and prothrombin complex concentrate may be considered (29) . Lastly, patients requiring targeted temperature management may exhibit prolongations of both PT and aPTT without evidence of bleeding diathesis (116) . Therefore, correction of coagulopathy in unselected patients without overt bleeding, is not currently recommended.", "cite_spans": [{"start": 122, "end": 125, "text": "(7)", "ref_id": "BIBREF7"}, {"start": 214, "end": 218, "text": "(29)", "ref_id": "BIBREF30"}, {"start": 517, "end": 521, "text": "(29)", "ref_id": "BIBREF30"}, {"start": 668, "end": 673, "text": "(116)", "ref_id": "BIBREF84"}], "ref_spans": [], "section": "Additional considerations."}, {"text": "DIC is common in many patients with critical illness (117) , including those with COVID-19 (7, 118) . It is uncertain whether COVID-19 has unique characteristics to cause direct activation of coagulation. The diagnosis of DIC is best established using the ISTH DIC score calculator (29) . Regular laboratory monitoring of platelet count, PT, D-dimer, and fibrinogen in patients with COVID-19 is important to diagnose worsening coagulopathy. The first step in management of DIC is to identify and treat the underlying condition(s). Bacterial superinfections should be treated aggressively.", "cite_spans": [{"start": 53, "end": 58, "text": "(117)", "ref_id": "BIBREF85"}, {"start": 91, "end": 94, "text": "(7,", "ref_id": "BIBREF7"}, {"start": 95, "end": 99, "text": "118)", "ref_id": "BIBREF86"}, {"start": 282, "end": 286, "text": "(29)", "ref_id": "BIBREF30"}], "ref_spans": [], "section": "Diagnosis and management."}, {"text": "In addition to preventing VTE, LMWH prophylaxis may decrease thrombin generation and modify the course of DIC. Preliminary results, albeit with small number of events and limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118). Longacting antiplatelet agents should be generally discontinued in most patients with DIC, unless required (e.g. recent ACS or stent implantation). For patients with moderate or severe COVID-19", "cite_spans": [], "ref_spans": [], "section": "Diagnosis and management."}, {"text": "and an indication for dual antiplatelet therapy (e.g. PCI within the past 3 months or recent MI) and with suspected or confirmed DIC without overt bleeding, in the absence of evidence decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet therapy if platelet count \u226550,000, reduce to single antiplatelet therapy if 25,000\u2264platelet count<50,000, and discontinue if platelets <25,000. However, these guidelines may be revised upward or downward depending on the individualized relative risk of stentrelated thrombotic complications vs. bleeding. Recovery from DIC is dependent on endogenous fibrinolysis breaking down the disseminated thrombi.", "cite_spans": [], "ref_spans": [], "section": "Diagnosis and management."}, {"text": "Clinically-overt bleeding is uncommon in the setting of COVID-19. However, when bleeding occurs in COVID-19-associated DIC, blood products support should be considered as per septic coagulopathy (119) . In summary, the mainstay of blood products transfusion are as follows: platelet concentrate to maintain platelet count >50 \u00d7 10 9 /L in DIC patients with active bleeding or >20 \u00d7 10 9 /L in those with a high risk of bleeding or requiring invasive procedures., ", "cite_spans": [{"start": 195, "end": 200, "text": "(119)", "ref_id": "BIBREF87"}], "ref_spans": [], "section": "Management of bleeding:"}, {"text": "The main goal of management for patients with known or new-onset thrombotic disease but without COVID-19 is to provide sufficient antithrombotic protection, while minimizing physical contact between patients and healthcare workers and health systems. Outpatient management or early discharge for acute VTE should be instituted when possible (120) (121) (122) , and early discharge after medication stabilization for low-risk ACS or PCI for high-risk ACS should be considered (100) (101) (102) . Telemedicine should be the preferred method of follow-up, and inperson visits should be reserved only for scenarios that cannot be addressed by telemedicine, or that may potentially warrant hospitalization.", "cite_spans": [{"start": 341, "end": 346, "text": "(120)", "ref_id": "BIBREF88"}, {"start": 347, "end": 352, "text": "(121)", "ref_id": "BIBREF89"}, {"start": 353, "end": 358, "text": "(122)", "ref_id": "BIBREF90"}, {"start": 475, "end": 480, "text": "(100)", "ref_id": "BIBREF68"}, {"start": 481, "end": 486, "text": "(101)", "ref_id": "BIBREF69"}, {"start": 487, "end": 492, "text": "(102)", "ref_id": "BIBREF70"}], "ref_spans": [], "section": "Management of Patients with Thromboembolic Disease without COVID-19"}, {"text": "In general, pharmacotherapy in patients with known thrombotic disease and without COVID-19, should be followed similar to the period prior to the pandemic. Although a recent document from the CDC indicated an increased risk of severe COVID-19 in patients receiving \"blood thinners\" (123) , there is no evidence that antiplatelet agents or anticoagulants, increase the risk of contracting COVID-19, or of developing severe COVID-19. Sufficient education should be provided to patients for self-monitoring of symptoms, and to avoid unnecessary emergency department visits for nuisance bleeding.", "cite_spans": [{"start": 282, "end": 287, "text": "(123)", "ref_id": "BIBREF91"}], "ref_spans": [], "section": "Management of Patients with Thromboembolic Disease without COVID-19"}, {"text": "For patients receiving VKAs, frequent INR monitoring may pose logistical challenges due to lockdowns and may unnecessarily increase the risk of being exposed to SARS-CoV-2.", "cite_spans": [], "ref_spans": [], "section": "Management of Patients with Thromboembolic Disease without COVID-19"}, {"text": "Therefore, thoughtful considerations should be given to potential alternatives, including using extended INR testing intervals if prior INRs have been stable (124) . Other alternatives include home-based INR checks, if this can be set up promptly, drive-through INR testing, or switching to a DOAC or LMWHs when clinically appropriate (Figure 3) . A summary of key recommendations is presented in Table 6 .", "cite_spans": [{"start": 158, "end": 163, "text": "(124)", "ref_id": "BIBREF92"}], "ref_spans": [{"start": 335, "end": 345, "text": "(Figure 3)", "ref_id": "FIGREF6"}, {"start": 397, "end": 404, "text": "Table 6", "ref_id": "TABREF6"}], "section": "Management of Patients with Thromboembolic Disease without COVID-19"}, {"text": "Considerations for healthcare workers.", "cite_spans": [], "ref_spans": [], "section": "Impact of COVID-19 on Healthcare Workers and Health Systems"}, {"text": "The CDC recommends contact and droplet personal PPE for healthcare workers in their routine care of patients with COVID-19. If an aerosol-generating procedure is being performed (e.g. intubation, extubation, cardiopulmonary resuscitation), additional airborne PPE with an N95 respirator is recommended. Use of telemedicine in place of in-person office visits is a strategy to minimize physical exposure. Further details have been discussed elsewhere (5, 104) .", "cite_spans": [{"start": 450, "end": 453, "text": "(5,", "ref_id": "BIBREF5"}, {"start": 454, "end": 458, "text": "104)", "ref_id": "BIBREF72"}], "ref_spans": [], "section": "Impact of COVID-19 on Healthcare Workers and Health Systems"}, {"text": "The following considerations specific to the care of patients with thrombotic disease may be useful. Over-the phone and telemedicine approaches should be considered for all non-urgent appointments. For necessary in-person visits, visitor restrictions and staggering of appointments are important considerations (125) . For patients with COVID-19 who require urgent procedures, such as interventions for ACS, high-risk PE, or critical limb ischemia, the fewest number of staff necessary should be involved. For patients without known infection, healthcare workers should screen patients for COVID-19 exposures or infectivity, consider appropriate PPE during the procedure, and apply disinfection techniques post-procedure, as outlined previously (126) . In patients who require, emergent cardiac catheterization with unknown COVID-19 status, airborne PPE with an N95 respirator and/or Powered Air Purifying Respirator is recommended (127, 128) .", "cite_spans": [{"start": 311, "end": 316, "text": "(125)", "ref_id": "BIBREF93"}, {"start": 745, "end": 750, "text": "(126)", "ref_id": "BIBREF94"}, {"start": 932, "end": 937, "text": "(127,", "ref_id": "BIBREF95"}, {"start": 938, "end": 942, "text": "128)", "ref_id": "BIBREF96"}], "ref_spans": [], "section": "Impact of COVID-19 on Healthcare Workers and Health Systems"}, {"text": "Active involvement of health systems with respect to the care of patients with thrombotic disease are critical to achieving good outcomes for both COVID-19-infected and uninfected patients. If feasible, resources should be allocated to enable at-home or drive-through INR checks. Further, system-based considerations should be made to monitor and make necessary adjustments to algorithms for management of suspected STEMI or severe PE requiring PERT teams. If procedures are deemed necessary for COVID-19 infected patients, specific protocols should be put into place regarding PPE use and room disinfection. (Figure 4) .", "cite_spans": [], "ref_spans": [{"start": 609, "end": 619, "text": "(Figure 4)", "ref_id": "FIGREF7"}], "section": "Considerations for health systems."}, {"text": "The WHO and government agencies have recognized the critical importance of public health interventions at the societal level (including social distancing and self-isolation) to decrease transmission rates and alleviate the burden on health systems (129) . In the most affected areas, governments have enacted mandatory home quarantine for all non-essential personnel (130) (131) (132) . There are several important issues to consider as these interventions relate to thrombotic disease.", "cite_spans": [{"start": 248, "end": 253, "text": "(129)", "ref_id": "BIBREF97"}, {"start": 367, "end": 372, "text": "(130)", "ref_id": "BIBREF99"}, {"start": 373, "end": 378, "text": "(131)", "ref_id": "BIBREF100"}, {"start": 379, "end": 384, "text": "(132)", "ref_id": "BIBREF101"}], "ref_spans": [], "section": "Public Health Considerations Related to Care for Thrombotic Disease"}, {"text": "First, given the recommendations to stay at home, with decreased daily activity and sedentary lifestyles, patients may be at increased risk for VTE (133) (134) (135) (136) (137) . Clinicians should be aware of this (especially in older adults and higher-risk patients) and provide education on the importance of home activities to mitigate this risk (138) . Second, as daily routines are disrupted, dietary changes (especially in daily intake of green vegetables, which are the major source of vitamin K in the Western diet) may affect patients who receive VKAs. As quarantine measures become more severe, changes in diet and vitamin K intake may impact INR values. Providers and patients should be aware of these risks, and patients should be advised to maintain stable diet to the best of their ability. Third, the COVID-19 pandemic has produced damaging economic effects (139) , with United Nations estimating that COVID-19 is likely to cost the world economy more than $2 trillion in 2020. These losses may adversely affect patients' treatment for thrombotic diseases. Socioeconomic disadvantage has been linked to higher rates of VTE and adverse outcomes (140, 141) . As the economic effects of COVID-19 continue to evolve, these communities may come under new and significant stress.", "cite_spans": [{"start": 148, "end": 153, "text": "(133)", "ref_id": "BIBREF102"}, {"start": 154, "end": 159, "text": "(134)", "ref_id": "BIBREF103"}, {"start": 160, "end": 165, "text": "(135)", "ref_id": "BIBREF104"}, {"start": 166, "end": 171, "text": "(136)", "ref_id": "BIBREF105"}, {"start": 172, "end": 177, "text": "(137)", "ref_id": "BIBREF106"}, {"start": 350, "end": 355, "text": "(138)", "ref_id": "BIBREF107"}, {"start": 874, "end": 879, "text": "(139)", "ref_id": null}, {"start": 1160, "end": 1165, "text": "(140,", "ref_id": "BIBREF109"}, {"start": 1166, "end": 1170, "text": "141)", "ref_id": "BIBREF110"}], "ref_spans": [], "section": "Public Health Considerations Related to Care for Thrombotic Disease"}, {"text": "More data and higher-quality data are required to learn how COVID-19 and thrombotic disease interact. Such data, ideally derived from prospective, multicenter, multinational studies, could help to elucidate the similarities and distinctions in disease presentation and outcomes of patients with COVID-19 and preexisting and incident thromboembolic disease, and help to identify management strategies to optimize outcomes in these patients. Currently, one large international registry of patients with venous thromboembolism (the Registro Informatizado", "cite_spans": [], "ref_spans": [], "section": "Future Directions and Conclusions"}, {"text": "and a dedicated adjudicated prospective registry to study COVID-19 and other cardiovascular outcomes is being initiated (CORONA-VTE, BWH Thrombosis Research Group; PI: G. Piazza).", "cite_spans": [], "ref_spans": [], "section": "Enfermedad TromboEmb\u00f3lica [RIETE]) (142) is incorporating data elements for COVID-19,"}, {"text": "A multicenter multinational ACS registry is has begun and a new AHA registry for cardiovascular care and outcomes of these patients. Special attention should also be given to patients with pre-existing thromboembolic disease who have limited access to care in the face of the COVID-19 pandemic, which has hindered transportation and limited the resources of the healthcare system.", "cite_spans": [], "ref_spans": [], "section": "Enfermedad TromboEmb\u00f3lica [RIETE]) (142) is incorporating data elements for COVID-19,"}, {"text": "Funding agencies, professional societies, and organizations with active patient participation will all play an important role when it comes to future research in this area. Funding agencies, including the National Institutes of Health (which has already responded swiftly) (143) should continue to pay specific attention to this pandemic. Coordination and cooperation are necessary to quickly address research priorities including those related to thrombotic disease ( Table 5) pandemic. Such guidance should supplement, rather than supplant, clinical decision-making.", "cite_spans": [{"start": 273, "end": 278, "text": "(143)", "ref_id": "BIBREF112"}], "ref_spans": [{"start": 469, "end": 477, "text": "Table 5)", "ref_id": null}], "section": "Enfermedad TromboEmb\u00f3lica [RIETE]) (142) is incorporating data elements for COVID-19,"}, {"text": "Nuances of conversations between patients and practitioners should be considered for appropriate patient-centered decisions.", "cite_spans": [], "ref_spans": [], "section": "Enfermedad TromboEmb\u00f3lica [RIETE]) (142) is incorporating data elements for COVID-19,"}, {"text": "In conclusion, thrombotic disease may be precedent factors or incident complications in patients with COVID-19. Important considerations for the preventive and therapeutic use of antithrombotic agents should be kept in mind to mitigate the thrombotic and hemorrhagic events in these high-risk patients. Funding agencies, professional societies, patients, clinicians, and investigators should work collaboratively to effectively and efficiently address numerous critical areas of knowledge gap.", "cite_spans": [], "ref_spans": [], "section": "Enfermedad TromboEmb\u00f3lica [RIETE]) (142) is incorporating data elements for COVID-19,"}, {"text": "thrombosis.", "cite_spans": [], "ref_spans": [], "section": "\u2022 Coronavirus disease 2019 (COVID-19) may predispose patients to arterial and venous"}, {"text": "\u2022 Initial series suggest the common occurrence of venous thromboembolic disease in patients with severe COVID-19. The optimal preventive strategy warrants further investigation.", "cite_spans": [], "ref_spans": [], "section": "\u2022 Coronavirus disease 2019 (COVID-19) may predispose patients to arterial and venous"}, {"text": "investigational COVID-19 therapies should be considered. ", "cite_spans": [], "ref_spans": [], "section": "\u2022 Drug-drug interactions between antiplatelet agents and anticoagulants with"}, {"text": "Administer at 50% of dose (do not administer if initial dose is 2.5 mg twice daily) \u2020", "cite_spans": [], "ref_spans": [], "section": "CYP3A4 and P-gp inhibition:"}, {"text": "Decrease dose to 80 mg once followed by 40 mg once daily", "cite_spans": [], "ref_spans": [], "section": "P-gp and ABCB1 inhibition:"}, {"text": "Do not co-administer CYP3A4 and P-gp inhibition: Do not co-administer Other drugs being studied to treat COVID-19 include bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, losartan, and pirfenidone. Drug-drug interactions between these medications and oral anticoagulants have yet to be identified. Bevacizumab has been reported to cause deep vein thrombosis (9%), arterial thrombosis (5%) and pulmonary embolism (1%). It is also reported to cause thrombocytopenia (58%).*Parenteral anticoagulants (including unfractionated or low-molecular weight heparins, bivalirudin, argatroban, and fondaparinux) are non CYP metabolized and don't interact with any of the investigational agents # Reported with interferon alpha. \u2020These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of these agents to be contraindicated. \u2021Interferon has been reported to cause pulmonary embolism (<5%), thrombosis (<5%), decreased platelet count (1-15% with Alfa-2b formulation), and ischemic stroke (<5%). \u00a7Sarilumab has been reported to cause decreased platelet count, with decreases to less than 100,000 mm 3 in 1% an 0.7% of patients on 200 mg and 150 mg doses, respectively. CYP: Cytochrome P system. |", "cite_spans": [], "ref_spans": [], "section": "P-gp inhibition:"}, {"text": "To determine the optimal method for risk assessment for outpatients with mild COVID-19 who are at risk of VTE The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "To determine the incidence acute coronary syndromes in population-based studies Patients with Moderate or severe COVID-19 without DIC (hospitalized) To determine the incidence and predictors of VTE among patients with COVID-19 who present with respiratory insufficiency and/or hemodynamic instability. These include lower extremity DVTs, central-line associated DVT in upper or lower extremities, and also PE.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "Prospective multicenter cohort (observational) data needed, these protocols should not interfere and could run in parallel with interventional trials which are planned or already underway. To develop an appropriate algorithm for the diagnosis of incident VTE in patients with COVID-19.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "D-dimer is elevated in many inpatients with COVID-19, although negative value may still be helpful. In some cases of COVID-19 with worsening hypoxemia, CTPA may be considered instead of non-contrast CT (which only assesses the pulmonary parenchyma. Unresolved issues include diagnostic tests for critically-ill patients, including those in prone position, with limited options for CTPA or ultrasonography. To determine the optimal total duration of prophylactic anticoagulation Ultrasound screening in select patients may need to be studied. To determine the optimal dose of prophylactic anticoagulation in specific populations (e.g. those with obesity or advanced kidney disease) Weight-adjusted prophylactic dosing for patients with obesity, or dosing based on creatinine clearance in patients with kidney disease require further investigation.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "To determine if LMWH constitutes the preferred method of pharmacological prophylaxis To determine the optimal method for risk stratification and VTE prophylaxis after hospital discharge", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding. To determine if routine use of higher doses of anticoagulants (i.e. higher than prophylactic doses as described in the international guidelines), confer net benefit An important question would be whether monitoring anti-Xa activity would be preferable over aPTT.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "To determine the incidence and predictors of type I acute myocardial infarction in patients with COVID-19, and to compare their process measures and outcomes with non-infected patients.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "To determine the potential role of agents including danaparoid, fondaparinux, and sulodexide in select patients with moderate/severe COVID-19.", "cite_spans": [], "ref_spans": [], "section": "Table 5. Areas Requiring Further Investigation Patients with Mild COVID-19 (outpatient) Comment"}, {"text": "To determine if routine use of pharmacological VTE prophylaxis or low or standard dose anticoagulation with UFH or LMWH is warranted (if no overt bleeding) A relevant question is whether prophylactic, or other, dose anticoagulation should be given to patients with DIC who do not have bleeding, even without immobility To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis To determine utility of other interventions including antithrombin concentrates.", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "Patients without COVID-19 but with co-morbidities, and homebound during the pandemic To determine the optimal method of screening and risk stratification for consideration of VTE prophylaxis", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding. To conduct population-level studies to determine the trends in incidence and outcomes of thrombotic disease in the period of reduced office visits Although telemedicine is reasonable to control the COVID-19 pandemic, potential adverse consequences on non-communicable disease, including thrombotic disease deserve investigation. aPTT: activated partial thromboplastin time, COVID-19: Coronavirus disease 2019; CTPA: computed tomography pulmonary angiography; LMWH: low-molecular weight heparin; PE: pulmonary embolism; VTE: Venous thromboembolism Patients with Mild COVID-19 (outpatient) For outpatients with mild COVID-19, increased mobility should be encouraged. Although indiscriminate use of pharmacological VTE prophylaxis should not be pursued, assessment for the risk of VTE and of bleeding is reasonable. Pharmacologic prophylaxis could be considered after risk assessment on an individual case basis for patients who have elevated risk VTE, without high bleeding risk.* There is no known risk of developing severe COVD-19 due to taking antithrombotic agents (i.e. antiplatelet agents or anticoagulants). If patients have been taking antithrombotic agents for prior known thrombotic disease, they should continue their antithrombotic agents as recommended. For outpatients on vitamin K antagonists who do not have recent stable INRs, and are unable to undergo home or drive-through INR testing, it is reasonable to transition the treatment DOACs if there are no contraindications and no problems with drug availability and affordability. If DOACs are not approved or available, low-molecular weight heparin can be considered as alternative.* Patients with Moderate or Severe COVID-19 without DIC (hospitalized) Hospitalized patients with COVID-19 should undergo risk stratification for VTE prophylaxis. For hospitalized patients with COVID-19 and not in DIC, prophylactic doses of anticoagulation can be administered to prevent VTE.*\u00a5 \u2020 If pharmacological prophylaxis is contraindicated, it is reasonable to consider intermittent pneumatic compression. For hospitalized patients with COVID-19 and not in DIC, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.* \u2021 Routine screening for VTE (e.g. bilateral lower extremity ultrasound) for hospitalized patients with COVID-19 with elevated D-Dimer (>1,500 ng/mL) cannot be recommended at this point & Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "For patients with moderate or severe COVID-19 and in DIC but without overt bleeding, prophylactic anticoagulation should be administered.*\u00a5 \u00a7 For hospitalized patients with COVID-19 with suspected or confirmed DIC, but no overt bleeding, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.*\u03b2 For patients with moderate or severe COVID-19 on chronic therapeutic anticoagulation, who develop suspected or confirmed DIC without overt bleeding, it is reasonable to consider the indication for anticoagulation and weigh with risk of bleeding when making clinical decisions regarding dose adjustments or discontinuation. The majority of authors of this manuscript recommended reducing the intensity of anticoagulation in this clinical circumstance, unless the risk of thrombosis considered to be exceedingly high. || For patients with moderate or severe COVID-19 and an indication for dual antiplatelet therapy (e.g. percutaneous coronary intervention within the past 3 months or recent myocardial infarction) and with suspected or confirmed DIC without overt bleeding, in the absence of evidence, decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet therapy if platelet count >50,000, reduce to single antiplatelet therapy if 25,000<platelet count<50,000; and discontinue if platelets <25,000. However, these guidelines may be revised upward or downward depending on the individualized relative risk of thrombotic complications vs. bleeding. For patients who were admitted and are now being discharged for COVID-19, routine screening for VTE risk is reasonable for consideration of pharmacological prophylaxis for up to 45 days postdischarge. Pharmacological prophylaxis should be considered if there is elevated risk for thrombotic events, without high bleeding risk. *# Ambulation and physical activity should be encouraged. Patients with COVID-19 presenting with ACS For presentations concerning for STEMI and COVID-19, clinicians should weigh the risks and severity of STEMI presentation with that of potential COVID-19 severity in the patient, as well as risk of COVID-19 to the individual clinicians and to the healthcare system at large. Decisions for primary percutaneous coronary intervention or fibrinolytic therapy should be informed by this assessment.* Patients without COVID-19 who have previously-known thrombotic disease There is no known risk of developing severe COVD-19 due to taking antithrombotic agents. Patients should continue their antithrombotic agents as recommended.", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases.", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "Patients without COVID-19 who develop new thrombotic disease To minimize risks associated with healthcare worker and patient in-person interactions, in-home treatment or early discharge should be prioritized. To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases.", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}, {"text": "Patients without COVID-19 but with co-morbid conditions (e.g. prior VTE, active cancer, major cardiopulmonary disease), who are homebound during the pandemic Recommendations include increased mobility, and risk assessment for the risk of VTE and risk of bleeding is reasonable. Administration of pharmacologic prophylaxis could be considered after risk assessment on an individual case basis for patients who have elevated risk for thrombotic events, without high bleeding risk. *Indicates recommendations as reached by consensus of at least 66% of authors determined via Delphi method. \u00a5Although high-quality data are lacking, some panel members (55%) considered it reasonable to use intermittent pneumatic compression in patients with severe COVID-19, in addition to pharmacological prophylaxis. Specific areas of concern included limited data on use in the prone position as well as potential high incidence of preexisting asymptomatic DVT. \u2020If VTE prophylaxis is considered, enoxaparin 40mg daily or similar LMWH regimen (e.g. dalteparin 5000U daily) can be administered. Subcutaneous heparin (5000U twice to three times per day) can be considered for patients with renal dysfunction (i.e. creatinine clearance <30 mL/min). \u2021While the majority of the writing group did make this recommendation, 31.6% of the group were in favor of intermediate-dose anticoagulation [e.g. enoxaparin 1mg/kg/day, or enoxaparin 40mg BID, or UFH with target aPTT of 50-70] and 5.2% considered therapeutic anticoagulation. &The majority of the investigators recommended against routine VTE screening (68%); however, the remaining members of the group (32%) recommended to consider such testing. \u00a7The majority of the investigators recommended prophylactic anticoagulation (54%). A minority of investigators (29.7%) voted for intermediate-dose parenteral anticoagulation in this setting, and 16.2% considered therapeutic anticoagulation. ||While the majority of investigators voted to reduce the intensity of anticoagulation if the indication were not acute (62%), this survey question did not meet prespecified cut-off of 66%. #The majority of the writing group recommended prophylaxis with DOACs (51%) and minority (24%) recommended LMWH, if available and appropriate. ACS: acute coronary syndrome; DOAC: direct oral anticoagulant, LMWH, low-molecular weight heparin; STEMI, ST-segment elevation myocardial infarction; UFH, unfractionated heparin; VTE, venous thromboembolism.", "cite_spans": [], "ref_spans": [], "section": "Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", "authors": [{"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "497--506", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Coronaviruses and the cardiovascular system: acute and long-term implications", "authors": [{"first": "T", "middle": ["Y"], "last": "Xiong", "suffix": ""}, {"first": "S", "middle": [], "last": "Redwood", "suffix": ""}, {"first": "B", "middle": [], "last": "Prendergast", "suffix": ""}, {"first": "M", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "Eur Heart J", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease, Circultion. 2020 (Epub Ahead of Print)", "authors": [{"first": "K", "middle": ["J"], "last": "Clerkin", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Fried", "suffix": ""}, {"first": "J", "middle": [], "last": "Rakhelkar", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic", "authors": [{"first": "E", "middle": [], "last": "Driggin", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Madhavan", "suffix": ""}, {"first": "B", "middle": [], "last": "Bikdeli", "suffix": ""}], "year": 2020, "venue": "J Am Coll Cardiol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Potential Effects of Coronaviruses on the Cardiovascular System: A Review", "authors": [{"first": "M", "middle": [], "last": "Madjid", "suffix": ""}, {"first": "P", "middle": [], "last": "Safavi-Naeini", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Solomon", "suffix": ""}, {"first": "O", "middle": [], "last": "Vardeny", "suffix": ""}], "year": 2020, "venue": "JAMA Cardiol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", "authors": [{"first": "N", "middle": [], "last": "Tang", "suffix": ""}, {"first": "D", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Sun", "suffix": ""}], "year": 2020, "venue": "J Thromb Haemost", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Hematologic parameters in patients with COVID-19 infection", "authors": [{"first": "B", "middle": ["E"], "last": "Fan", "suffix": ""}, {"first": "Vcl", "middle": [], "last": "Chong", "suffix": ""}, {"first": "Ssw", "middle": [], "last": "Chan", "suffix": ""}], "year": 2020, "venue": "Am J Hematol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome", "authors": [{"first": "T", "middle": ["W"], "last": "Lew", "suffix": ""}, {"first": "T", "middle": ["K"], "last": "Kwek", "suffix": ""}, {"first": "D", "middle": [], "last": "Tai", "suffix": ""}], "year": 2003, "venue": "JAMA", "volume": "290", "issn": "", "pages": "374--80", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Influenza and cardiovascular disease: is there a causal relationship?", "authors": [{"first": "M", "middle": [], "last": "Madjid", "suffix": ""}, {"first": "I", "middle": [], "last": "Aboshady", "suffix": ""}, {"first": "I", "middle": [], "last": "Awan", "suffix": ""}, {"first": "S", "middle": [], "last": "Litovsky", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "Casscells", "suffix": ""}], "year": 2004, "venue": "Tex Heart Inst J", "volume": "31", "issn": "", "pages": "4--13", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report", "authors": [{"first": "C", "middle": [], "last": "Kearon", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Akl", "suffix": ""}, {"first": "J", "middle": [], "last": "Ornelas", "suffix": ""}], "year": 2016, "venue": "Chest", "volume": "149", "issn": "", "pages": "315--52", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein", "authors": [{"first": "A", "middle": ["C"], "last": "Walls", "suffix": ""}, {"first": "Y", "middle": ["J"], "last": "Park", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Tortorici", "suffix": ""}, {"first": "A", "middle": [], "last": "Wall", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Mcguire", "suffix": ""}, {"first": "D", "middle": [], "last": "Veesler", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target", "authors": [{"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Penninger", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Slutsky", "suffix": ""}], "year": 2020, "venue": "Intensive Care Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1", "authors": [{"first": "N", "middle": [], "last": "Van Doremalen", "suffix": ""}, {"first": "T", "middle": [], "last": "Bushmaker", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Morris", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "authors": [{"first": "P", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "X", "middle": ["L"], "last": "Yang", "suffix": ""}, {"first": "X", "middle": ["G"], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in", "authors": [{"first": "D", "middle": [], "last": "Wang", "suffix": ""}, {"first": "B", "middle": [], "last": "Hu", "suffix": ""}, {"first": "C", "middle": [], "last": "Hu", "suffix": ""}], "year": null, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Clinical Characteristics of Coronavirus Disease 2019 in China", "authors": [{"first": "W", "middle": ["J"], "last": "Guan", "suffix": ""}, {"first": "Z", "middle": ["Y"], "last": "Ni", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention", "authors": [{"first": "Z", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Mcgoogan", "suffix": ""}], "year": null, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease", "authors": [{"first": "C", "middle": [], "last": "Wu", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cai", "suffix": ""}], "year": 2019, "venue": "JAMA Intern Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", "authors": [{"first": "F", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "T", "middle": [], "last": "Yu", "suffix": ""}, {"first": "R", "middle": [], "last": "Du", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Inflammation and thrombosis: the clot thickens", "authors": [{"first": "P", "middle": [], "last": "Libby", "suffix": ""}, {"first": "D", "middle": ["I"], "last": "Simon", "suffix": ""}], "year": 2001, "venue": "Circulation", "volume": "103", "issn": "", "pages": "1718--1738", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "M", "middle": [], "last": "Plebani", "suffix": ""}, {"first": "Michael", "middle": [], "last": "Henry", "suffix": ""}, {"first": "B", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "Clin Chim Acta", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Favaloro", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection", "authors": [{"first": "H", "middle": [], "last": "Han", "suffix": ""}, {"first": "L", "middle": [], "last": "Yang", "suffix": ""}, {"first": "R", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "Clin Chem Lab Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Laboratory abnormalities in patients with COVID-2019 infection", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "M", "middle": [], "last": "Plebani", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study", "authors": [{"first": "X", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "J", "middle": [], "last": "Xu", "suffix": ""}], "year": 2020, "venue": "Lancet Respir Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19", "authors": [{"first": "Y", "middle": [], "last": "Gao", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": [], "last": "Han", "suffix": ""}], "year": 2020, "venue": "J Med Virol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "Shortened activated partial thromboplastin time: causes and management", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "G", "middle": ["L"], "last": "Salvagno", "suffix": ""}, {"first": "L", "middle": [], "last": "Ippolito", "suffix": ""}, {"first": "M", "middle": [], "last": "Franchini", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Favaloro", "suffix": ""}], "year": 2010, "venue": "Blood Coagul Fibrinolysis", "volume": "21", "issn": "", "pages": "459--63", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology", "authors": [{"first": "M", "middle": [], "last": "Levi", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Toh", "suffix": ""}, {"first": "J", "middle": [], "last": "Thachil", "suffix": ""}, {"first": "H", "middle": ["G"], "last": "Watson", "suffix": ""}], "year": 2009, "venue": "Br J Haematol", "volume": "145", "issn": "", "pages": "24--33", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the", "authors": [{"first": "S", "middle": ["V"], "last": "Konstantinides", "suffix": ""}, {"first": "G", "middle": [], "last": "Meyer", "suffix": ""}, {"first": "C", "middle": [], "last": "Becattini", "suffix": ""}], "year": 2019, "venue": "Eur Heart J", "volume": "41", "issn": "", "pages": "543--603", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group", "authors": [{"first": "M", "middle": ["M"], "last": "Samama", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Cohen", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Darmon", "suffix": ""}], "year": 1999, "venue": "N Engl J Med", "volume": "341", "issn": "", "pages": "793--800", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients", "authors": [{"first": "", "middle": [], "last": "Randomized", "suffix": ""}], "year": 2004, "venue": "Circulation", "volume": "110", "issn": "", "pages": "874--883", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial", "authors": [{"first": "A", "middle": ["T"], "last": "Cohen", "suffix": ""}, {"first": "B", "middle": ["L"], "last": "Davidson", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Gallus", "suffix": ""}], "year": 2006, "venue": "BMJ", "volume": "332", "issn": "", "pages": "325--334", "other_ids": {}}, "BIBREF36": {"ref_id": "b36", "title": "American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients", "authors": [{"first": "H", "middle": ["J"], "last": "Schunemann", "suffix": ""}, {"first": "M", "middle": [], "last": "Cushman", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Burnett", "suffix": ""}], "year": 2018, "venue": "Blood Adv", "volume": "2", "issn": "", "pages": "3198--3225", "other_ids": {}}, "BIBREF37": {"ref_id": "b37", "title": "Prevention of VTE in nonsurgical patients", "authors": [{"first": "S", "middle": ["R"], "last": "Kahn", "suffix": ""}, {"first": "W", "middle": [], "last": "Lim", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Dunn", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", "authors": [], "year": 2012, "venue": "Antithrombotic Therapy and Prevention of Thrombosis", "volume": "141", "issn": "", "pages": "195--226", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap?", "authors": [{"first": "I", "middle": ["E"], "last": "Albertsen", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Nielsen", "suffix": ""}], "year": 2018, "venue": "Thromb Haemost", "volume": "118", "issn": "", "pages": "1686--1687", "other_ids": {}}, "BIBREF40": {"ref_id": "b40", "title": "Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients", "authors": [{"first": "K", "middle": ["M"], "last": "Ho", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Tan", "suffix": ""}], "year": 2013, "venue": "Circulation", "volume": "128", "issn": "", "pages": "1003--1023", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Exploring the impact of route of administration on medication acceptance in hospitalized patients: Implications for venous thromboembolism prevention", "authors": [{"first": "V", "middle": ["O"], "last": "Popoola", "suffix": ""}, {"first": "F", "middle": [], "last": "Tavakoli", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Lau", "suffix": ""}], "year": 2017, "venue": "Thromb Res", "volume": "160", "issn": "", "pages": "109--113", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy", "authors": [{"first": "S", "middle": ["M"], "last": "Bates", "suffix": ""}, {"first": "A", "middle": [], "last": "Rajasekhar", "suffix": ""}, {"first": "S", "middle": [], "last": "Middeldorp", "suffix": ""}], "year": 2018, "venue": "Blood Adv", "volume": "2", "issn": "", "pages": "3317--3359", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "Reducing the risk of venous thromboembolism during pregnancy and the puerperium", "authors": [], "year": 2015, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis", "authors": [{"first": "R", "middle": [], "last": "Ikesaka", "suffix": ""}, {"first": "A", "middle": [], "last": "Delluc", "suffix": ""}, {"first": "Le", "middle": [], "last": "Gal", "suffix": ""}, {"first": "G", "middle": [], "last": "Carrier", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2014, "venue": "Thromb Res", "volume": "133", "issn": "", "pages": "682--689", "other_ids": {}}, "BIBREF46": {"ref_id": "b46", "title": "Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial", "authors": [{"first": "R", "middle": ["D"], "last": "Hull", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "Schellong", "suffix": ""}, {"first": "V", "middle": ["F"], "last": "Tapson", "suffix": ""}], "year": 2010, "venue": "Ann Intern Med", "volume": "153", "issn": "", "pages": "8--18", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients", "authors": [{"first": "A", "middle": ["T"], "last": "Cohen", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Harrington", "suffix": ""}, {"first": "S", "middle": ["Z"], "last": "Goldhaber", "suffix": ""}], "year": 2016, "venue": "N Engl J Med", "volume": "375", "issn": "", "pages": "534--578", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "Rivaroxaban for thromboprophylaxis in acutely ill medical patients", "authors": [{"first": "A", "middle": ["T"], "last": "Cohen", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Spiro", "suffix": ""}, {"first": "H", "middle": ["R"], "last": "Buller", "suffix": ""}], "year": 2013, "venue": "N Engl J Med", "volume": "368", "issn": "", "pages": "513--536", "other_ids": {}}, "BIBREF49": {"ref_id": "b49", "title": "Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness", "authors": [{"first": "A", "middle": ["C"], "last": "Spyropoulos", "suffix": ""}, {"first": "W", "middle": [], "last": "Ageno", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Albers", "suffix": ""}], "year": 2018, "venue": "N Engl J Med", "volume": "379", "issn": "", "pages": "1118--1127", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis", "authors": [{"first": "A", "middle": ["C"], "last": "Spyropoulos", "suffix": ""}, {"first": "C", "middle": [], "last": "Lipardi", "suffix": ""}, {"first": "J", "middle": [], "last": "Xu", "suffix": ""}], "year": 2020, "venue": "TH Open", "volume": "4", "issn": "", "pages": "59--65", "other_ids": {}}, "BIBREF51": {"ref_id": "b51", "title": "Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials", "authors": [{"first": "F", "middle": [], "last": "Dentali", "suffix": ""}, {"first": "N", "middle": [], "last": "Mumoli", "suffix": ""}, {"first": "D", "middle": [], "last": "Prisco", "suffix": ""}, {"first": "A", "middle": [], "last": "Fontanella", "suffix": ""}, {"first": "Di", "middle": [], "last": "Minno", "suffix": ""}, {"first": "M", "middle": ["N"], "last": "", "suffix": ""}], "year": 2017, "venue": "Thromb Haemost", "volume": "117", "issn": "", "pages": "606--617", "other_ids": {}}, "BIBREF52": {"ref_id": "b52", "title": "Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment", "authors": [{"first": "M", "middle": [], "last": "Schindewolf", "suffix": ""}, {"first": "J", "middle": ["I"], "last": "Weitz", "suffix": ""}], "year": 2020, "venue": "Thromb Haemost", "volume": "120", "issn": "", "pages": "14--26", "other_ids": {}}, "BIBREF53": {"ref_id": "b53", "title": "Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study", "authors": [{"first": "A", "middle": ["C"], "last": "Spyropoulos", "suffix": ""}, {"first": "C", "middle": [], "last": "Lipardi", "suffix": ""}, {"first": "J", "middle": [], "last": "Xu", "suffix": ""}], "year": 2019, "venue": "Clin Appl Thromb Hemost", "volume": "25", "issn": "", "pages": "", "other_ids": {}}, "BIBREF54": {"ref_id": "b54", "title": "D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial", "authors": [{"first": "A", "middle": ["T"], "last": "Cohen", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Spiro", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Spyropoulos", "suffix": ""}], "year": 2011, "venue": "American Heart Association. Circulation", "volume": "12", "issn": "", "pages": "1788--830", "other_ids": {}}, "BIBREF55": {"ref_id": "b55", "title": "Pulmonary Embolism Response Teams", "authors": [{"first": "N", "middle": [], "last": "Reza", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Dudzinski", "suffix": ""}], "year": 2015, "venue": "Current Treatment Options in Cardiovascular Medicine", "volume": "17", "issn": "", "pages": "", "other_ids": {}}, "BIBREF56": {"ref_id": "b56", "title": "Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members", "authors": [{"first": "G", "middle": ["D"], "last": "Barnes", "suffix": ""}, {"first": "C", "middle": [], "last": "Kabrhel", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Courtney", "suffix": ""}], "year": 2016, "venue": "Chest", "volume": "150", "issn": "", "pages": "1414--1417", "other_ids": {}}, "BIBREF57": {"ref_id": "b57", "title": "Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions", "authors": [{"first": "R", "middle": [], "last": "Rosovsky", "suffix": ""}, {"first": "K", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "A", "middle": [], "last": "Sista", "suffix": ""}, {"first": "B", "middle": [], "last": "Rivera-Lebron", "suffix": ""}, {"first": "C", "middle": [], "last": "Kabrhel", "suffix": ""}], "year": 2019, "venue": "Res Pract Thromb Haemost", "volume": "3", "issn": "", "pages": "315--330", "other_ids": {}}, "BIBREF58": {"ref_id": "b58", "title": "Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association", "authors": [{"first": "J", "middle": [], "last": "Giri", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Sista", "suffix": ""}, {"first": "I", "middle": [], "last": "Weinberg", "suffix": ""}], "year": 2019, "venue": "Circulation", "volume": "140", "issn": "", "pages": "774--801", "other_ids": {}}, "BIBREF59": {"ref_id": "b59", "title": "Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a metaanalysis", "authors": [{"first": "S", "middle": [], "last": "Chatterjee", "suffix": ""}, {"first": "A", "middle": [], "last": "Chakraborty", "suffix": ""}, {"first": "I", "middle": [], "last": "Weinberg", "suffix": ""}], "year": 2014, "venue": "JAMA", "volume": "311", "issn": "", "pages": "2414--2435", "other_ids": {}}, "BIBREF60": {"ref_id": "b60", "title": "Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis", "authors": [{"first": "B", "middle": [], "last": "Bikdeli", "suffix": ""}, {"first": "S", "middle": [], "last": "Chatterjee", "suffix": ""}, {"first": "N", "middle": ["R"], "last": "Desai", "suffix": ""}], "year": 2017, "venue": "J Am Coll Cardiol", "volume": "70", "issn": "", "pages": "1587--1597", "other_ids": {}}, "BIBREF61": {"ref_id": "b61", "title": "Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism", "authors": [{"first": "D", "middle": [], "last": "Jimenez", "suffix": ""}, {"first": "B", "middle": [], "last": "Bikdeli", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Marshall", "suffix": ""}, {"first": "V", "middle": [], "last": "Tapson", "suffix": ""}], "year": 2018, "venue": "Clin Chest Med", "volume": "39", "issn": "", "pages": "569--581", "other_ids": {}}, "BIBREF62": {"ref_id": "b62", "title": "Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital", "authors": [{"first": "D", "middle": ["L"], "last": "Ain", "suffix": ""}, {"first": "M", "middle": [], "last": "Albaghdadi", "suffix": ""}, {"first": "J", "middle": [], "last": "Giri", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF64": {"ref_id": "b64", "title": "Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis", "authors": [{"first": "S", "middle": [], "last": "Vedantham", "suffix": ""}, {"first": "S", "middle": ["Z"], "last": "Goldhaber", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Julian", "suffix": ""}], "year": 2017, "venue": "N Engl J Med", "volume": "377", "issn": "", "pages": "2240--2252", "other_ids": {}}, "BIBREF65": {"ref_id": "b65", "title": "Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Lavie", "suffix": ""}], "year": 2020, "venue": "Prog Cardiovasc Dis", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection", "authors": [{"first": "J", "middle": ["C"], "last": "Kwong", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Schwartz", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Campitelli", "suffix": ""}], "year": 2018, "venue": "N Engl J Med", "volume": "378", "issn": "", "pages": "345--353", "other_ids": {}}, "BIBREF67": {"ref_id": "b67", "title": "Role of acute infection in triggering acute coronary syndromes", "authors": [{"first": "V", "middle": ["F"], "last": "Corrales-Medina", "suffix": ""}, {"first": "M", "middle": [], "last": "Madjid", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Musher", "suffix": ""}], "year": 2010, "venue": "Lancet Infect Dis", "volume": "10", "issn": "", "pages": "83--92", "other_ids": {}}, "BIBREF68": {"ref_id": "b68", "title": "AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines", "authors": [{"first": "E", "middle": ["A"], "last": "Amsterdam", "suffix": ""}, {"first": "N", "middle": ["K"], "last": "Wenger", "suffix": ""}, {"first": "R", "middle": ["G"], "last": "Brindis", "suffix": ""}], "year": 2014, "venue": "Circulation", "volume": "130", "issn": "", "pages": "2354--94", "other_ids": {}}, "BIBREF69": {"ref_id": "b69", "title": "ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", "authors": [{"first": "P", "middle": ["T"], "last": "O&apos;gara", "suffix": ""}, {"first": "F", "middle": ["G"], "last": "Kushner", "suffix": ""}, {"first": "D", "middle": ["D"], "last": "Ascheim", "suffix": ""}], "year": 2013, "venue": "J Am Coll Cardiol", "volume": "61", "issn": "4", "pages": "78--140", "other_ids": {}}, "BIBREF70": {"ref_id": "b70", "title": "ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC)", "authors": [{"first": "B", "middle": [], "last": "Ibanez", "suffix": ""}, {"first": "S", "middle": [], "last": "James", "suffix": ""}, {"first": "S", "middle": [], "last": "Agewall", "suffix": ""}], "year": 2017, "venue": "European heart journal", "volume": "39", "issn": "", "pages": "119--177", "other_ids": {}}, "BIBREF71": {"ref_id": "b71", "title": "ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)", "authors": [{"first": "M", "middle": [], "last": "Roffi", "suffix": ""}, {"first": "C", "middle": [], "last": "Patrono", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Collet", "suffix": ""}], "year": 2015, "venue": "Eur Heart J", "volume": "37", "issn": "", "pages": "267--315", "other_ids": {}}, "BIBREF72": {"ref_id": "b72", "title": "Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI", "authors": [{"first": "Fgp", "middle": [], "last": "Welt", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Shah", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Aronow", "suffix": ""}], "year": 2020, "venue": "J Am Coll Cardiol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF73": {"ref_id": "b73", "title": "How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital", "authors": [{"first": "J", "middle": [], "last": "Zeng", "suffix": ""}, {"first": "J", "middle": [], "last": "Huang", "suffix": ""}, {"first": "L", "middle": [], "last": "Pan", "suffix": ""}], "year": 2020, "venue": "Intensive Care Medicine", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF74": {"ref_id": "b74", "title": "Venous thromboembolic disease: An observational study in medical-surgical intensive care unit patients", "authors": [{"first": "D", "middle": [], "last": "Cook", "suffix": ""}, {"first": "J", "middle": [], "last": "Attia", "suffix": ""}, {"first": "B", "middle": [], "last": "Weaver", "suffix": ""}, {"first": "E", "middle": [], "last": "Mcdonald", "suffix": ""}, {"first": "M", "middle": [], "last": "Meade", "suffix": ""}, {"first": "M", "middle": [], "last": "Crowther", "suffix": ""}], "year": 2000, "venue": "Journal of Critical Care", "volume": "15", "issn": "", "pages": "127--132", "other_ids": {}}, "BIBREF75": {"ref_id": "b75", "title": "Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis", "authors": [{"first": "C", "middle": [], "last": "Minet", "suffix": ""}, {"first": "L", "middle": [], "last": "Potton", "suffix": ""}, {"first": "A", "middle": [], "last": "Bonadona", "suffix": ""}], "year": 2015, "venue": "Crit Care", "volume": "19", "issn": "", "pages": "287--287", "other_ids": {}}, "BIBREF76": {"ref_id": "b76", "title": "Prevention of venous thromboembolism in the ICU", "authors": [{"first": "W", "middle": [], "last": "Geerts", "suffix": ""}, {"first": "R", "middle": [], "last": "Selby", "suffix": ""}], "year": 2003, "venue": "Chest", "volume": "124", "issn": "", "pages": "357--363", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study", "authors": [{"first": "M", "middle": ["A"], "last": "Crowther", "suffix": ""}, {"first": "E", "middle": [], "last": "Mcdonald", "suffix": ""}, {"first": "M", "middle": [], "last": "Johnston", "suffix": ""}, {"first": "D", "middle": [], "last": "Cook", "suffix": ""}], "year": 2002, "venue": "Blood Coagulation & Fibrinolysis", "volume": "13", "issn": "", "pages": "49--52", "other_ids": {}}, "BIBREF78": {"ref_id": "b78", "title": "Introduction to Drug Pharmacokinetics in the Critically III Patient", "authors": [{"first": "B", "middle": ["S"], "last": "Smith", "suffix": ""}, {"first": "D", "middle": [], "last": "Yogaratnam", "suffix": ""}, {"first": "K", "middle": ["E"], "last": "Levasseur-Franklin", "suffix": ""}, {"first": "A", "middle": [], "last": "Forni", "suffix": ""}, {"first": "J", "middle": [], "last": "Fong", "suffix": ""}], "year": 2012, "venue": "Chest", "volume": "141", "issn": "", "pages": "1327--1336", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis", "authors": [{"first": "S", "middle": ["R"], "last": "Kahn", "suffix": ""}, {"first": "W", "middle": [], "last": "Lim", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Dunn", "suffix": ""}], "year": 2012, "venue": "Chest", "volume": "141", "issn": "", "pages": "195--226", "other_ids": {}}, "BIBREF80": {"ref_id": "b80", "title": "Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review", "authors": [{"first": "M", "middle": ["C"], "last": "Sklar", "suffix": ""}, {"first": "E", "middle": [], "last": "Sy", "suffix": ""}, {"first": "L", "middle": [], "last": "Lequier", "suffix": ""}, {"first": "E", "middle": [], "last": "Fan", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Kanji", "suffix": ""}], "year": 2016, "venue": "Ann Am Thorac Soc", "volume": "13", "issn": "", "pages": "2242--2250", "other_ids": {}}, "BIBREF81": {"ref_id": "b81", "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan", "authors": [{"first": "F", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "T", "middle": [], "last": "Yu", "suffix": ""}, {"first": "R", "middle": [], "last": "Du", "suffix": ""}], "year": null, "venue": "China: a retrospective cohort study. The Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF82": {"ref_id": "b82", "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine", "authors": [{"first": "X", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "J", "middle": [], "last": "Xu", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF83": {"ref_id": "b83", "title": "ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. v1.4 ed: Extracorporeal Life Support Organization", "authors": [{"first": "(", "middle": [], "last": "Elso", "suffix": ""}, {"first": "", "middle": [], "last": "Elso", "suffix": ""}], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF84": {"ref_id": "b84", "title": "Therapeutic temperature management after cardiac arrest and the risk of bleeding: systematic review and meta-analysis", "authors": [{"first": "H", "middle": [], "last": "Stockmann", "suffix": ""}, {"first": "A", "middle": [], "last": "Krannich", "suffix": ""}, {"first": "T", "middle": [], "last": "Schroeder", "suffix": ""}, {"first": "C", "middle": [], "last": "Storm", "suffix": ""}], "year": 2014, "venue": "Resuscitation", "volume": "85", "issn": "", "pages": "1494--503", "other_ids": {}}, "BIBREF85": {"ref_id": "b85", "title": "Bleeding and coagulopathies in critical care", "authors": [{"first": "B", "middle": ["J"], "last": "Hunt", "suffix": ""}], "year": 2014, "venue": "N Engl J Med", "volume": "370", "issn": "", "pages": "847--59", "other_ids": {}}, "BIBREF86": {"ref_id": "b86", "title": "Angiotensin-converting enzyme 2 is an essential regulator of heart function", "authors": [{"first": "M", "middle": ["A"], "last": "Crackower", "suffix": ""}, {"first": "R", "middle": [], "last": "Sarao", "suffix": ""}, {"first": "G", "middle": ["Y"], "last": "Oudit", "suffix": ""}], "year": 2002, "venue": "Nature", "volume": "417", "issn": "", "pages": "822--830", "other_ids": {}}, "BIBREF87": {"ref_id": "b87", "title": "Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines", "authors": [{"first": "H", "middle": [], "last": "Wada", "suffix": ""}, {"first": "J", "middle": [], "last": "Thachil", "suffix": ""}, {"first": "Di", "middle": [], "last": "Nisio", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2013, "venue": "J Thromb Haemost", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF88": {"ref_id": "b88", "title": "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, noninferiority trial", "authors": [{"first": "D", "middle": [], "last": "Aujesky", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Roy", "suffix": ""}, {"first": "F", "middle": [], "last": "Verschuren", "suffix": ""}], "year": 2011, "venue": "Lancet", "volume": "378", "issn": "", "pages": "41--49", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis", "authors": [{"first": "W", "middle": [], "last": "Zondag", "suffix": ""}, {"first": "J", "middle": [], "last": "Kooiman", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Klok", "suffix": ""}, {"first": "O", "middle": ["M"], "last": "Dekkers", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Huisman", "suffix": ""}], "year": 2013, "venue": "Eur Respir J", "volume": "42", "issn": "", "pages": "134--178", "other_ids": {}}, "BIBREF90": {"ref_id": "b90", "title": "Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial", "authors": [{"first": "S", "middle": [], "last": "Barco", "suffix": ""}, {"first": "I", "middle": [], "last": "Schmidtmann", "suffix": ""}, {"first": "W", "middle": [], "last": "Ageno", "suffix": ""}], "year": 2020, "venue": "Eur Heart J", "volume": "41", "issn": "", "pages": "509--518", "other_ids": {}}, "BIBREF91": {"ref_id": "b91", "title": "Implementation of Mitigation Strategies for Communities with Local COVID-19 Transmission", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF92": {"ref_id": "b92", "title": "Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial", "authors": [{"first": "S", "middle": [], "last": "Schulman", "suffix": ""}, {"first": "S", "middle": [], "last": "Parpia", "suffix": ""}, {"first": "C", "middle": [], "last": "Stewart", "suffix": ""}, {"first": "L", "middle": [], "last": "Rudd-Scott", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Julian", "suffix": ""}, {"first": "M", "middle": [], "last": "Levine", "suffix": ""}], "year": 2011, "venue": "Ann Intern Med", "volume": "155", "issn": "", "pages": "201--204", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", "authors": [{"first": "F", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "T", "middle": [], "last": "Yu", "suffix": ""}, {"first": "R", "middle": [], "last": "Du", "suffix": ""}], "year": 2020, "venue": "Lancet March", "volume": "11", "issn": "", "pages": "30566--30569", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Catheterization Laboratory Considerations During the Coronavirus (COVID 19) Pandemic: A Joint statement from the American College of Cardiology (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI)", "authors": [{"first": "Fgp", "middle": [], "last": "Welt", "suffix": ""}, {"first": "", "middle": [], "last": "Sp", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Aronow", "suffix": ""}], "year": null, "venue": "Journal of the American College of Cardiology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF95": {"ref_id": "b95", "title": "CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic", "authors": [{"first": "Y", "middle": [], "last": "Han", "suffix": ""}, {"first": "H", "middle": [], "last": "Zeng", "suffix": ""}, {"first": "H", "middle": [], "last": "Jiang", "suffix": ""}], "year": 2020, "venue": "Circulation", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF96": {"ref_id": "b96", "title": "Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From", "authors": [{"first": "G", "middle": ["G"], "last": "Stefanini", "suffix": ""}, {"first": "E", "middle": [], "last": "Azzolini", "suffix": ""}, {"first": "G", "middle": [], "last": "Condorelli", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF97": {"ref_id": "b97", "title": "Every country needs to take boldest actions to stop COVID-19", "authors": [{"first": "Hhp", "middle": [], "last": "Kluge", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF98": {"ref_id": "b98", "title": "World Health Organization, Regional Office for Europe", "authors": [{"first": "Denmark", "middle": [], "last": "Copenhagen", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF99": {"ref_id": "b99", "title": "COVID-19): 15-day Pause", "authors": [], "year": 2019, "venue": "Centers for Disease Control and Prevention. Coronavirus Disease", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "State of Israel Ministry of Health. The Novel Coronavirus (COVID-19). Israel: State of Israel Ministry of Health", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Official website of Hubei Provincial People's Government. Hubei strengthens epidemic prevention and control: implement strictest 24-hour closed management for all communities in urban and rural areas", "authors": [], "year": 2020, "venue": "The Paper", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF102": {"ref_id": "b102", "title": "Functional Impairment and Risk of Venous Thrombosis in Older Adults", "authors": [{"first": "M", "middle": ["J"], "last": "Engbers", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Blom", "suffix": ""}, {"first": "M", "middle": [], "last": "Cushman", "suffix": ""}, {"first": "F", "middle": ["R"], "last": "Rosendaal", "suffix": ""}, {"first": "A", "middle": [], "last": "Van Hylckama Vlieg", "suffix": ""}], "year": 2017, "venue": "J Am Geriatr Soc", "volume": "65", "issn": "", "pages": "2003--2008", "other_ids": {}}, "BIBREF103": {"ref_id": "b103", "title": "Physical inactivity and idiopathic pulmonary embolism in women: prospective study", "authors": [{"first": "C", "middle": [], "last": "Kabrhel", "suffix": ""}, {"first": "R", "middle": [], "last": "Varraso", "suffix": ""}, {"first": "S", "middle": ["Z"], "last": "Goldhaber", "suffix": ""}, {"first": "E", "middle": [], "last": "Rimm", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Camargo", "suffix": ""}, {"first": "Jr", "middle": [], "last": "", "suffix": ""}], "year": 2011, "venue": "Bmj", "volume": "343", "issn": "", "pages": "", "other_ids": {}}, "BIBREF104": {"ref_id": "b104", "title": "Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study", "authors": [{"first": "P", "middle": ["L"], "last": "Lutsey", "suffix": ""}, {"first": "B", "middle": ["A"], "last": "Virnig", "suffix": ""}, {"first": "S", "middle": ["B"], "last": "Durham", "suffix": ""}], "year": 2010, "venue": "Am J Public Health", "volume": "100", "issn": "", "pages": "1506--1519", "other_ids": {}}, "BIBREF105": {"ref_id": "b105", "title": "When the game demons take real lives: a call for global awareness raising for venous thromboembolism", "authors": [{"first": "B", "middle": [], "last": "Bikdeli", "suffix": ""}], "year": 2012, "venue": "Thromb Res", "volume": "129", "issn": "", "pages": "", "other_ids": {}}, "BIBREF106": {"ref_id": "b106", "title": "eThrombosis: the 21st century variant of venous thromboembolism associated with immobility", "authors": [{"first": "R", "middle": [], "last": "Beasley", "suffix": ""}, {"first": "N", "middle": [], "last": "Raymond", "suffix": ""}, {"first": "S", "middle": [], "last": "Hill", "suffix": ""}, {"first": "M", "middle": [], "last": "Nowitz", "suffix": ""}, {"first": "R", "middle": [], "last": "Hughes", "suffix": ""}], "year": 2003, "venue": "Eur Respir J", "volume": "21", "issn": "", "pages": "374--380", "other_ids": {}}, "BIBREF107": {"ref_id": "b107", "title": "World Health Organization Regional Office for Europe. Stay physically active during self-quarantine. World Health Organization", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF109": {"ref_id": "b109", "title": "Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a population-based study", "authors": [{"first": "D", "middle": [], "last": "Kort", "suffix": ""}, {"first": "N", "middle": [], "last": "Van Rein", "suffix": ""}, {"first": "Fjm", "middle": [], "last": "Van Der Meer", "suffix": ""}], "year": 2017, "venue": "J Thromb Haemost", "volume": "15", "issn": "", "pages": "2352--2360", "other_ids": {}}, "BIBREF110": {"ref_id": "b110", "title": "Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up", "authors": [{"first": "N", "middle": [], "last": "Isma", "suffix": ""}, {"first": "J", "middle": [], "last": "Merlo", "suffix": ""}, {"first": "H", "middle": [], "last": "Ohlsson", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Svensson", "suffix": ""}, {"first": "B", "middle": [], "last": "Lindblad", "suffix": ""}, {"first": "A", "middle": [], "last": "Gottsater", "suffix": ""}], "year": 2013, "venue": "J Thromb Thrombolysis", "volume": "36", "issn": "", "pages": "58--64", "other_ids": {}}, "BIBREF111": {"ref_id": "b111", "title": "Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE)", "authors": [{"first": "B", "middle": [], "last": "Bikdeli", "suffix": ""}, {"first": "D", "middle": [], "last": "Jimenez", "suffix": ""}, {"first": "M", "middle": [], "last": "Hawkins", "suffix": ""}], "year": 2018, "venue": "Thromb Haemost", "volume": "118", "issn": "", "pages": "214--224", "other_ids": {}}, "BIBREF112": {"ref_id": "b112", "title": "COVID-19): Information for NIH Applicants and Recipients of NIH Funding", "authors": [], "year": 2019, "venue": "Coronavirus Disease", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF113": {"ref_id": "b113", "title": "Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis", "authors": [{"first": "P", "middle": ["Y"], "last": "Chong", "suffix": ""}, {"first": "P", "middle": [], "last": "Chui", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Ling", "suffix": ""}], "year": 2004, "venue": "Arch Pathol Lab Med", "volume": "128", "issn": "", "pages": "195--204", "other_ids": {}}, "BIBREF114": {"ref_id": "b114", "title": "Acute Respiratory Distress Syndrome in Critically Ill Patients With Severe Acute Respiratory Syndrome", "authors": [{"first": "Twk", "middle": [], "last": "Lew", "suffix": ""}, {"first": "T-K", "middle": [], "last": "Kwek", "suffix": ""}, {"first": "D", "middle": [], "last": "Tai", "suffix": ""}], "year": 2003, "venue": "JAMA", "volume": "290", "issn": "", "pages": "374--380", "other_ids": {}}, "BIBREF115": {"ref_id": "b115", "title": "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study", "authors": [{"first": "J", "middle": ["S"], "last": "Peiris", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Chu", "suffix": ""}, {"first": "V", "middle": ["C"], "last": "Cheng", "suffix": ""}], "year": 2003, "venue": "Lancet", "volume": "361", "issn": "", "pages": "1767--72", "other_ids": {}}, "BIBREF116": {"ref_id": "b116", "title": "Coronary plaque instability in severe acute respiratory syndrome", "authors": [{"first": "K", "middle": ["L"], "last": "Tsui", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Leung", "suffix": ""}, {"first": "L", "middle": ["Y"], "last": "Yam", "suffix": ""}], "year": 2005, "venue": "Int J Cardiol", "volume": "99", "issn": "", "pages": "471--473", "other_ids": {}}, "BIBREF117": {"ref_id": "b117", "title": "Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)", "authors": [{"first": "T", "middle": [], "last": "Umapathi", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Kor", "suffix": ""}, {"first": "N", "middle": [], "last": "Venketasubramanian", "suffix": ""}], "year": 2004, "venue": "Journal of Neurology", "volume": "251", "issn": "", "pages": "1227--1231", "other_ids": {}}, "BIBREF118": {"ref_id": "b118", "title": "Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis", "authors": [{"first": "Rsm", "middle": [], "last": "Wong", "suffix": ""}, {"first": "A", "middle": [], "last": "Wu", "suffix": ""}, {"first": "K", "middle": ["F"], "last": "To", "suffix": ""}], "year": 2003, "venue": "BMJ", "volume": "326", "issn": "", "pages": "1358--1362", "other_ids": {}}, "BIBREF119": {"ref_id": "b119", "title": "Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis", "authors": [{"first": "J", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "H", "middle": [], "last": "Chu", "suffix": ""}, {"first": "C", "middle": [], "last": "Li", "suffix": ""}], "year": 2013, "venue": "The Journal of Infectious Diseases", "volume": "209", "issn": "", "pages": "1331--1342", "other_ids": {}}, "BIBREF120": {"ref_id": "b120", "title": "Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4", "authors": [{"first": "K", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": [], "last": "Wohlford-Lenane", "suffix": ""}, {"first": "S", "middle": [], "last": "Perlman", "suffix": ""}], "year": 2016, "venue": "J Infect Dis", "volume": "213", "issn": "", "pages": "712--734", "other_ids": {}}, "BIBREF121": {"ref_id": "b121", "title": "State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans", "authors": [], "year": 2013, "venue": "PLoS Curr", "volume": "5", "issn": "", "pages": "", "other_ids": {}}, "BIBREF122": {"ref_id": "b122", "title": "H1N1-Induced Venous Thromboembolic Events? Results of a Single-Institution Case Series", "authors": [{"first": "E", "middle": [], "last": "Dimakakos", "suffix": ""}, {"first": "D", "middle": [], "last": "Grapsa", "suffix": ""}, {"first": "I", "middle": [], "last": "Vathiotis", "suffix": ""}], "year": 2016, "venue": "Open Forum Infect Dis", "volume": "3", "issn": "", "pages": "214--214", "other_ids": {}}, "BIBREF123": {"ref_id": "b123", "title": "Pandemic H1N1 Influenza Infection and Vascular Thrombosis", "authors": [{"first": "P", "middle": ["E"], "last": "Bunce", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "High", "suffix": ""}, {"first": "M", "middle": [], "last": "Nadjafi", "suffix": ""}, {"first": "K", "middle": [], "last": "Stanley", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Liles", "suffix": ""}, {"first": "M", "middle": ["D"], "last": "Christian", "suffix": ""}], "year": 2011, "venue": "Clinical Infectious Diseases", "volume": "52", "issn": "", "pages": "14--17", "other_ids": {}}, "BIBREF124": {"ref_id": "b124", "title": "Influenza Infection Exerts Prominent Inflammatory and Thrombotic Effects on the Atherosclerotic Plaques of Apolipoprotein E-Deficient Mice", "authors": [{"first": "M", "middle": [], "last": "Naghavi", "suffix": ""}, {"first": "P", "middle": [], "last": "Wyde", "suffix": ""}, {"first": "S", "middle": [], "last": "Litovsky", "suffix": ""}], "year": 2003, "venue": "Circulation", "volume": "107", "issn": "", "pages": "762--768", "other_ids": {}}, "BIBREF125": {"ref_id": "b125", "title": "Association of influenza vaccination with reduced risk of venous thromboembolism", "authors": [{"first": "T", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "L", "middle": [], "last": "Carcaillon", "suffix": ""}, {"first": "I", "middle": [], "last": "Martinez", "suffix": ""}], "year": 2009, "venue": "Thromb Haemost", "volume": "102", "issn": "", "pages": "1259--64", "other_ids": {}}, "BIBREF126": {"ref_id": "b126", "title": "Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection", "authors": [{"first": "J", "middle": ["C"], "last": "Kwong", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Schwartz", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Campitelli", "suffix": ""}], "year": 2018, "venue": "New England Journal of Medicine", "volume": "378", "issn": "", "pages": "345--353", "other_ids": {}}, "BIBREF127": {"ref_id": "b127", "title": "Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination", "authors": [{"first": "L", "middle": [], "last": "Smeeth", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Thomas", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Hall", "suffix": ""}, {"first": "R", "middle": [], "last": "Hubbard", "suffix": ""}, {"first": "P", "middle": [], "last": "Farrington", "suffix": ""}, {"first": "P", "middle": [], "last": "Vallance", "suffix": ""}], "year": 2004, "venue": "New England Journal of Medicine", "volume": "351", "issn": "", "pages": "2611--2618", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study", "authors": [{"first": "C", "middle": [], "last": "Warren-Gash", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Hayward", "suffix": ""}, {"first": "H", "middle": [], "last": "Hemingway", "suffix": ""}], "year": 2012, "venue": "J Infect Dis", "volume": "206", "issn": "", "pages": "1652--1661", "other_ids": {}}, "BIBREF129": {"ref_id": "b129", "title": "Intravascular coagulation complicating influenza A virus infection", "authors": [{"first": "A", "middle": ["M"], "last": "Davison", "suffix": ""}, {"first": "D", "middle": [], "last": "Thomson", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Robson", "suffix": ""}], "year": 1973, "venue": "Br Med J", "volume": "1", "issn": "", "pages": "654--659", "other_ids": {}}, "BIBREF130": {"ref_id": "b130", "title": "Disseminated intravascular clotting complicating viral pneumonia due to influenza", "authors": [{"first": "N", "middle": ["A"], "last": "Talley", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Assumpcao", "suffix": ""}], "year": 1971, "venue": "Med J Aust", "volume": "2", "issn": "", "pages": "763--769", "other_ids": {}}, "BIBREF131": {"ref_id": "b131", "title": "Disseminated intravascular coagulation and acute renal failure in influenza A2 infection", "authors": [{"first": "A", "middle": ["N"], "last": "Whitaker", "suffix": ""}, {"first": "I", "middle": [], "last": "Bunce", "suffix": ""}, {"first": "E", "middle": ["R"], "last": "Graeme", "suffix": ""}], "year": 1974, "venue": "Med J Aust", "volume": "2", "issn": "", "pages": "196--201", "other_ids": {}}, "BIBREF132": {"ref_id": "b132", "title": "Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan", "authors": [{"first": "Y", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ma", "suffix": ""}, {"first": "W", "middle": [], "last": "Zuo", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF133": {"ref_id": "b133", "title": "Coronaviruses and the cardiovascular system: acute and long-term implications", "authors": [{"first": "T-Y", "middle": [], "last": "Xiong", "suffix": ""}, {"first": "S", "middle": [], "last": "Redwood", "suffix": ""}, {"first": "B", "middle": [], "last": "Prendergast", "suffix": ""}, {"first": "M", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "European Heart Journal", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF134": {"ref_id": "b134", "title": "Laboratory abnormalities in patients with COVID-2019 infection", "authors": [{"first": "G", "middle": [], "last": "Lippi", "suffix": ""}, {"first": "M", "middle": [], "last": "Plebani", "suffix": ""}], "year": 2020, "venue": "Clinical Chemistry and Laboratory Medicine", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF135": {"ref_id": "b135", "title": "Inhibition of warfarin activity by ribavirin", "authors": [{"first": "S", "middle": [], "last": "Schulman", "suffix": ""}], "year": 2002, "venue": "Ann Pharmacother", "volume": "36", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "size and lack of validation. At this moment, while practitioners use a variety of prophylactic, intermediate, or therapeutic doses of anticoagulants in patients, the optimal dosing in patients with severe COVID-19 remains unknown and warrants further prospective investigation. The majority of panel members consider prophylactic anticoagulation, although a minority consider intermediate-dose or therapeutic dose to be reasonable.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "fresh frozen plasma (FFP) (15-25 mL/kg) in patients with active bleeding with either prolonged PT and/or aPTT ratios (>1.5 times normal) or decreased fibrinogen (<1.5 g/L), fibrinogen concentrate or cryoprecipitate to patients with persisting severe hypofibrinogenemia (<1.5 g/L), and prothrombin complex concentrate (PCC) if FFP transfusion is not possible. With the existing data, tranexamic acid should not be used routinely in COVID-19-associated DIC.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Professional societies, along with other partners, have an important role in knowledge generation and dissemination for various aspects of COVID-19(5,84,104), as well as leading byexample. Illustrative examples include the responsible and wise decisions by the ACC to cancel the 2020 Annual Scientific Sessions, the SCAI to cancel the 2020 Annual Scientific Sessions, and the ISTH to cancel the XXVIII Congress of the ISTH to promote social distancing and to avoid further spread of the disease. Enabling meetings to continue virtually, as with the recent ACC scientific sessions (in this case at no charge) further promotes knowledge dissemination and sense of community, allowing a semblance or normality in challenging times. Many professional societies, including the ACC, the American Heart Association (AHA), American Society of Hematology, ESC, the ISTH, and others, are compiling COVID-related resources in dedicated websites. Professional societies can further foster collaborative knowledge generation by supporting multicenter multinational original research studies to address the pressing clinical or laboratory questions", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Organizations such as the Patient-Centered Outcomes Research Institute (PCORI) and the North American Thrombosis Forum (NATF) can ensure the voices and concerns of patients are at the forefront of research questions. Professional societies, including the AHA, ESC, ISTH, IUA, and others should promote knowledge generation and dissemination and advocacy in this challenging climate.The current manuscript has provided an interim summary and guidance for considerations related to thrombotic disease and antithrombotic therapy during the COVID-19", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Variability in resources and testing strategies, and in contracting COVID-19 after exposure to SARS-CoV-2. Such variability explains the dissimilar population rates of the infection, and the distinct case fatality rates, across various regions and countries. Inflammatory response, increased age, and bed-ridden status -which are more frequently observed in severe COVID-19-may contribute to thrombosis and adverse outcomes. Coronavirus Disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), VTE indicates venous thromboembolism.", "latex": null, "type": "figure"}, "FIGREF5": {"text": "Risk stratification of acute coronary syndromes and venous thromboembolism with COVID-19. Proposed algorithm to risk stratify patients based on severity of ACS, VTE, and COVID-19 presentations. *High-risk ACS refers to patients with hemodynamic instability, left ventricular dysfunction or focal wall motion abnormality, or worsening or refractory symptoms. High-risk VTE refers to patients with pulmonary embolism who are hemodynamically unstable, have evidence of right ventricular dysfunction or dilatation, or with worsening or refractory symptoms. \u2020High-risk COVID-19 refers to patients with high suspicion for or confirmed COVID-19, including individuals with high viral load, symptomatic with coughing/sneezing or other respiratory symptoms and at risk for requiring intubation and aerosolizing viral particles. \u2021Hemodynamic support includes intra-aortic balloon pump, percutaneous ventricular assist device, and extracorporeal membrane oxygenation. Hemodynamic monitoring refers to Swan-Ganz catheter for invasive hemodynamic assessment. For potential drug-drug interactions, please refer to Tables 4 and 5. ACS indicates acute coronary syndrome; GDMT, guideline-directed medical therapy; TTE, transthoracic echocardiogram; VTE, venous thromboembolism.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Considerations for Switching Vitamin-K Antagonists (VKAs) Due to Limitations with Access to Care or Healthcare Resources During COVID-19 Pandemic. If switching the anticoagulant agent is planned, care should be taken to be sure that the patient is able to afford and receive the alternative therapy. Contraindications to DOACs include mechanical heart valves, valvular AF, pregnancy or breastfeeding, APLS, and co-administration of medications including strong CYP3A and P-glycoprotein inhibitors (-azole medications, HIV protease inhibitors [dependent on DOAC, may just require dose reduction], CYP3A4 inducers (antiepileptics), St. John's Wort, rifampin, etc. Patient education about stable dietary habits while receiving VKA is also important. If DOACs area not available or approved by insurance, LMWHs could be used in select cases. Abbreviations: AF: atrial fibrillation, APLS: antiphospholipid syndrome, DOAC: direct oral anticoagulant, INR: international normalized ratio, LMWH: low-molecular weight heparin, VKA: vitamin-K antagonist.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "Considerations for Thrombotic Disease for Patients, Healthcare Providers, and Health Systems and Professional Societies During the COVID-19 Pandemic. The approach to safe evaluation and management of thrombotic disease in patients with COVID-19 has several levels of involvement. Hospitalized patients with existing VTE should continue on anticoagulation with consideration of drug-drug interactions, especially with antiviral medications (Table 2). Hospitalized patients with reduced mobility should be started on VTE prophylaxis. Patients who are discharged or not hospitalized should continue recommended anticoagulation therapy. Telemedicine and drive-through or home INR checks can reduce the risk of exposure of both patients and healthcare providers to COVID-19 while assuring proper management of anticoagulation. In appropriate cases, consider switching VKAs to DOACs to diminish the need for frequent INR checks (see Figure 4). Healthcare workers should continue existing precautions including use of PPE and minimizing individual contact with COVID-19 patients. If emergent procedures for thrombotic disease (e.g. cardiac catheterization, pulmonary thrombectomy) are needed, procedure rooms should be disinfected and the use of negative pressure operating rooms should be implemented as available. Expedited funding for observational and randomized control trials in management of thrombotic disease is encouraged. aPTT: activated partial thromboplastin time, DOAC: direct oral anticoagulant, INR: international normalized ratio, PT: prothrombin time, PPE: personal protective equipment, VKA: vitamin-K antagonist, VTE: venous thromboembolism. Central Illustration. Postulated Mechanisms of Coagulopathy and Pathogenesis of Thrombosis in COVID-19. A) Sars-COV-2 infection activates an inflammatory response, leading to release of inflammatory mediators. Endothelial and hemostatic activation ensues, with decreased levels of TFPI and increased tissue factor. The inflammatory response to severe infection is marked by lymphopenia, and thrombocytopenia. Liver injury may lead to decreased coagulation and antithrombin formation. B) COVID-19 may be associated with hemostatic derangement and elevated troponin. C) Increased thromboembolic state results in venous thromboembolism, myocardial infarction, or in case of further hemostatic derangement; disseminated intravascular coagulation. COPD: chronic obstructive pulmonary disease; CRP: creactive protein; FDP: fibrin degradation product; HF: heart failure; TFPI: tissue factor pathway inhibitor; IL: interleukin; LDH: lactate dehydrogenase; PT: prothrombin time.", "latex": null, "type": "figure"}, "FIGREF8": {"text": "Systematic review of literature published prior to February 24, 2020 suggests elevations in PT and D-dimer levels were associated with poor prognosis in patients with COVID-19.(165) ACS = acute coronary syndrome; aPTT = activated partial thromboplastin time; COVID-19 = coronavirus disease of 2019; DIC = disseminated intravascular coagulation; DVT = deep vein thrombosis; ICU= intensive care unit; MERS = Middle East Respiratory Syndrome; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; PE = pulmonary embolism; PT = prothrombin time; SARS = severe acute respiratory syndrome; STEMI = ST-elevation myocardial infarction; VTE = venous thromboembolism.", "latex": null, "type": "figure"}, "FIGREF9": {"text": "Reported increase in expression of CYP3A4 (major pathway): No dose adjustment recommended Reported increase in expression of CYP3A4 (major pathway): No dose adjustment recommended Azithromycin Unknown mechanism: Decreased dose may be needed P-gp inhibition: May increase plasma concentration. No dose adjustment recommended P-gp inhibition: Decrease dose to 80 mg once followed by 40 mg daily P-gp inhibition: VTE: Limit dose to 30 mg daily. Non-valvular AF:", "latex": null, "type": "figure"}, "TABREF0": {"text": "summarizes interactions between investigational drugs for COVID-19 and commonly administered oral anticoagulants. Lopinavir/ritonavir has the potential to also affect choice and dosage of a number of anticoagulants. For example, vitamin K antagonists, apixaban, and betrixaban may all require dose adjustment, while edoxaban and rivaroxaban should not be co-administered with lopinavir/ritonavir. Tocilizumab, an IL-6 inhibitor, increases expression of CYP3A4; however, no anticoagulant dose adjustments are currently recommended with concomitant use of tocilizumab at this time. There are no major drug-drug interactions between investigational COVID-19 therapies and parenteral anticoagulants. Although the focus of the current manuscript is primarily related to VTE and ACS, the guidance provided for antithrombotic considerations is broadly relevant across other clinical indications.", "latex": null, "type": "table"}, "TABREF1": {"text": "Intermediate-risk hemodynamically stable patients (intermediate-low risk, or intermediate-high risk PE according to ESC classification, sub-massive PE according to prior classifications) (49,87,91,94) should be managed initially with anticoagulation and close monitoring. In case of further deterioration, rescue systemic fibrinolysis should be considered, with catheter-directed options as an alternative. For patients with overt hemodynamic instability (high-risk PE according to the ESC classification, massive PE according to prior classifications) (49,87,91,94) systemic fibrinolysis is indicated, with catheter-based therapies reserved for scenarios that are not suitable for systemic fibrinolysis. If infection control settings are equal,", "latex": null, "type": "table"}, "TABREF2": {"text": "Xiao M, Zhang S et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020. De Bruyne B, Pijls NH et al. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary", "latex": null, "type": "table"}, "TABREF3": {"text": "Select Summary of Thrombotic and Thromboembolic Events During Viral Outbreaks", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Proposed Mechanisms </td><td>Event Type </td><td>\u00a0</td><td>Epidemiological data </td></tr><tr><td>Severe Acute Respiratory Syndrome (SARS) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2022 Inflammatory cytokine release \u2022 Critical illness </td><td>Venous Thromboembolism \u2022 \u2022 </td><td>\u00a0</td><td>Retrospective analysis of 46 critically ill patise nwtith SARS showed 11 DVT and 7 PE events.(145) Case series of 8 SARS positive ICU patients. Auyt oidpesntified PE in 4, and DVT in 3 individuals.(1)4 4</td></tr><tr><td>\u2022 Therapeutic risk factors.(144) </td><td>Arterial Thrombotic Events \u2022 \u2022 </td><td>\u00a0</td><td>In a prospective series of 75 patients, 2 patients died of acute myocardial infarction (within 3-week period).(146) Case report of an NSTEMI patient who received PuCt Is bubsequently developed STEMI several hours, laterconcerning for immune-mediated plaque instabil1it4y7.() </td></tr><tr><td>Other \u2022 \u2022 </td><td>In a retrospective analysis of 157 patients withR Spatients and DIC developed in 4 patients.(149) </td><td>In a case series of 206 patients with SARS, 5 doepveedl large artery ischemic stroke with DIC presine n2t/ 5.(148) A, isolated, subclinical elevations in aPTT weortee dn in 96 </td></tr><tr><td>Middle East Respiratory Syndrome (MERS-CoV) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2022 Nonspecific mechanism; potentially similar to SARS. Models suggest elevated inflammatory cytokine levels.(150) \u2022 Transgenic murine models show evidence of microvascular thrombosis.(151) </td><td>Other \u2022 </td><td>coagulopathy.(152) </td><td>In a series of 161 cases of MERS (confirmed andb apbrloe), at least 2 were reported to have a consivuem pt</td></tr><tr><td>Influenza </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2022 Possible de novo pulmonary emboli in certain cases.(153) </td><td>Venous Thromboembolism \u2022 \u2022 </td><td>\u00a0</td><td>Retrospective study of 119 patients showed 4 VTeEn tesv in patients receiving prophylactic anticoatgiounla.(154) Case series describes 7 PEs in patients with innzflau epneumonia. In 6/7 there was no evidence of D(1V5T3.) </td></tr><tr><td>\u2022 Acute inflammation and decreased </td><td>\u2022 </td><td>\u00a0</td><td>A multicenter, observational, case-control stud=y1 (4n54) suggests lower VTE rates are associated i nwfiluthenza </td></tr><tr><td>mobility in hospitalized patients.(154) </td><td>vaccination (odds ratio: 0.74; 95% CI: 0.57-0.9175)6.() </td></tr><tr><td>\u2022 Possible thrombosis due to rupture of pre-\n</td><td>\u2022 </td><td>\u00a0</td><td>This is a representative but not comprehensive list of associated studies. </td></tr><tr><td>existing high risk plaques.(99) \u2022 Platelet aggregation over inflamed atherosclerotic plaques noted in animal models.(155) </td><td>Arterial Thrombotic Events \u2022 \u2022 \u2022 </td><td>\u00a0</td><td>A self-controlled study of 364 patients hospitadli zweith acute myocardial infarction found an increeda sincidence ratio (IR=6.05, 95% confidence interval: 3.86 t5o0 9). for myocardial infarction during periods afitnefrl uenza compared with controls.(157) Similar evidence esx ins tprior studies.(158,159) A retrospective cohort study of 119 patients resp 3or atrterial thrombotic events, two of which hadE SMTI (154). This is a representative but not comprehensive list of associated studies. </td></tr><tr><td>Other \u2022 </td><td>\u00a0</td><td>DIC has been described with influenza infectiona inu mber of case reports and small case series-1 (6126)0. </td></tr><tr><td>COVID-19 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2022 </td><td>Venous \u2022 </td><td>\u00a0</td><td>In a preprint retrospective study, 10/25 patienhtso wunderwent computed tomography pulmonary angpiohgyr ahad </td></tr><tr><td>\u2022 </td><td>Thromboembolism \u2022 </td><td>acute PE </td><td>h(ttps://papers.ssrn.com/sol3/papers.cfm?abstra=c3t5_4id8771) Two-case series of acute pulmonary embolism wesrecr dibeed in patients hospitalized with COVID-19.( 83)</td></tr><tr><td>\u00a0</td><td>\u2022 </td><td>In a study from 3 hospitals from the Netherland1s%, 3 of 184 critically-ill patients with COVID-19 ha VdTE. </td></tr><tr><td>\u2022 </td><td>and Arterial Thrombotic Events \u2022 \u2022 </td><td>\u00a0</td><td>Evidence regarding ACS with concurrent COVID-19e icntfion is limited to anecdotal reports. A pre-p rsiinntgle-center retrospective study reported 11 cases otef aisccuhemic stroke among 221 patients with COVID -19(https://papers.ssrn.com/sol3/papers.cfm?abstra=c3t5_5id0025) Data are continuing to emerge regarding the risk of thrombotic events associated with COVID-19 infection, and an international registry for ACS is planned. Please see text for more detail. </td></tr><tr><td>\u00a0</td><td>Retrospective analysis of 183 patients found non-survivors had significantly higher D-dimer and PT values, compared with survivors. Further, 15/21 (71.4%) of non-survivmorest criteria for DIC, versus 1/162 (0.6%) of surovrisv.(7) Systematic review of literature published priorF teob ruary 24, 2020 suggests elevations in PT andim De-rd levels were associated with poor prognosis in patients with CIDO-V19.(165) ACS = acute coronary syndrome; aPTT = activatedtia pl athrromboplastin time; COVID-19 = coronaviruss edaise of 2019; DIC = disseminated intravasculagr ucloaation; DVT = deep vein </td><td>Mechanistic understanding continues to evolve. Factors may include inflammatory cytokine release and critical illness/therapeutic risk factors. SARS-CoV-2 binds cells expressing angiotensin converting enzyme 2 (163) this may mediate further mechanisms of injury.(164) </td><td>Other </td></tr></table></body></html>"}, "TABREF4": {"text": "Association Between Coagulation Abnormalities or Markers of Thrombosis and Hemostasis and Clinical Outcomes in Patients with COVID-19", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>Han 2020 (N=94)(24) </td><td>Huang 2020 (N=41)(1) </td><td>Yang 2020 (N=52)(26) </td><td>Zhou et al (N=191)(20) </td><td>Gao 2020 (N=43)(27) </td><td>Wang 2020 (N=138)(16) </td><td>Wu 2020 (N=201)(19) </td><td>Tang 2020 (N=183)(7) </td><td>Lippi 2020 (N=1779)(2\n2) </td><td>Lippi 2020 (N=553)(23) Lippi 2020 (N=341)(36) </td></tr><tr><td>Platelet count </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Setting of Comparison </td><td>ICU vs. non-ICU </td><td>Dead vs. alive </td><td>Dead vs. alive </td><td>\u00a0</td><td>ICU vs. non-ICU </td><td>Dead vs. alive </td><td>\u00a0</td><td>Dead vs. alive </td><td>\u00a0</td></tr><tr><td>Platelet Count </td><td>\u00a0</td><td>196 (165-\n263) vs. 149 (131-263) </td><td>191 (74) vs. 164 (63) </td><td>166 (107-229) vs. 220 (168-271) </td><td>\u00a0</td><td>142 (110-202) vs. 165 (125-188) </td><td>162 (111-231) vs. 204 (137-263) </td><td>\u00a0</td><td>-48 (-57 - - 39)*^ </td><td>\u00a0</td></tr><tr><td>D-dimer (mg/L) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Setting of Comparison </td><td>Severe vs. non-severe </td><td>ICU vs. non-\n</td><td>\u00a0</td><td>Dead vs. </td><td>Severe vs. non-severe </td><td>ICU vs. non-\n</td><td>Dead vs. </td><td>Dead vs. </td><td>\u00a0</td><td>Severe vs. non-severe </td></tr><tr><td>ICU </td><td>\u00a0</td><td>alive </td><td>ICU </td><td>alive </td><td>alive </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>D-dimer (mg/L) </td><td>19.1 vs. 2.1 </td><td>2.4 (0.6-\n14.4) vs. 0.5 </td><td>5.2 (1.5-21.1) vs. 0.6 </td><td>0.5 (0.3-0.9) vs. 0.2 (0.2-\n</td><td>0.4 (0.2-13.2) vs. 0.2 </td><td>4.0 (1.0-11.0) vs. 0.5 </td><td>2.1 (0.8-5.3) vs. 0.6 (0.4-\n</td><td>3.0 (2.5-3.5)* </td></tr></table></body></html>"}, "TABREF5": {"text": "Potential Drug Interactions Between Anticoagulants * and Investigational Therapies for COVID-19", "latex": null, "type": "table"}, "TABREF6": {"text": "Summary of Consensus Recommendation on Antithrombotic Therapy During the COVID-19 Pandemic", "latex": null, "type": "table"}}, "back_matter": [{"text": "The authors would like to thank Kathryn Mikkelsen, MBA, from the North American Thrombosis Forum, and Adriana Vison\u00e0, MD, from the European Society of Vascular Medicine for their comments related to this initiative. The authors would like to credit Julie Der Nigoghossian for assistance with graphic design.", "cite_spans": [], "ref_spans": [], "section": "Acknowledgments"}, {"text": "No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported inducer of CYP3A4 (major pathway):"}, {"text": "No dose adjustment recommended. TocilizumabInhibits IL-6 receptor: may potentially mitigate cytokine release syndrome symptoms in severely ill patientsReported increase in expression of 2C19 (major pathway) and 1A2, 2B6, and 3A4 (minor pathways: No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported inducer of CYP3A4 (major pathway):"}, {"text": "No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of 3A4 (major pathway) and 2C9 and 2C19 (minor pathway):"}, {"text": "No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of 3A4 (major pathway):"}, {"text": "Binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6R\u03b1 and mIL-6R\u03b1) and has been shown to inhibit IL-6-mediated signaling: may potentially mitigate cytokine release syndrome symptoms in severely ill patientsReported increase in expression of 3A4 (minor pathways: No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended. Sarilumab"}, {"text": "No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of 3A4 (major pathway):"}, {"text": "No dose adjustment recommended.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of CYP3A4(major pathway):"}, {"text": "No dose adjustment recommended.Other drugs being studied to treat COVID-19 include azithromycin, bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, interferon, losartan, methylprednisolone, pirfenidone, and ribavirin. Drug-drug interactions between these medications and antiplatelet agents have yet to be identified. *Cangrelor, aspirin, dipyridamole, and glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab) are not known to interact with investigational therapies for COVID-19. \u2020Monitoring of P2Y12 levels can be assessed through the VerifyNow assay, or others. Evaluation of effect of protease inhibitors on P2Y12 inhibitors has not been extensively studied. Dose reduction recommendations for P2Y12 inhibitors or P2Y12 platelet function assay monitoring is not commonly practiced.", "cite_spans": [], "ref_spans": [], "section": "Reported increase in expression of 3A4 (major pathway):"}]}